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The aim of this study was to assess the therapeutic efficacy of high affinity human-derived 
antibodies (NI-203-26C11) showing high affinity against pathologically misfolded forms of 
human islet polypeptide (hIAPP) in a transgenic homozygous mouse model expressing hIAPP 
(FVB/N-Tg(Ins2-IAPP)RHF/Soel/J). Transgenic homozygous male mice received weekly 
intraperitoneal injections of either NI 203-26C11 or phosphate-buffered saline (PBS 
10ml/kg), for three months. Hemizygous mice receiving PBS were used as control. The 
efficacy of the immunotherapy was assessed by determining body weight, plasma levels of 
insulin and glucose during glucose tolerance tests at different time points and by assessing the 
hIAPP-derived amyloid load in the pancreas and islet morphology at the end of the three 
month experimental period.  
While hemizygous mice showed no symptoms of spontaneous disease, both groups of 
homozygous mice, independently of treatment, developed diabetes mellitus due to β-cell 
death, associated with impaired insulin secretion (hypoinsulinemia). The treatment with NI 
203-26C11 did not improve fasting glycaemia or glucose tolerance in homozygous mice 
compared to the PBS-treated controls. The NI 203.26C11 antibody administration also did not 
show beneficial effects in preventing or slowing the progression of diabetes in this mouse 
strain. Nevertheless, the antibody administration was well tolerated and did not elicit any 
toxic or systemic immunoreaction.  
 











Das Ziel dieser Studie war es, die therapeutische Wirksamkeit von Antikörpern (NI-203-
26C11), die eine hohe Affinität gegen pathologisch gefaltet Formen von humanem Islet 
Amyloid Polypeptide (hIAPP) aufweisen, in einem transgenrn Mausmodell zu untersuchen, 
das hIAPP exprimiert. Während drei Monaten wurden, transgene männliche Mäuse 
wochentliche mit NI 203-26C11 oder Phosphat-gepufferter NaCl Lösung (PBS, 10ml/kg) 
behandelt. Hemizygote Mäuse, denen ebenfalls PBS appliziert wurde, dienten als 
Kontrolltiere. Die Wirksamkeit der Immunotherapie wurde anhand des Körpergewichts, 
Plasma-Insulin- und Glukose-Spiegel während eines Glukose-Toleranztests, der hIAPP-
Amyloidablagerungen im Pankreas und der Inselmorphologie beurteilt. Während hemizygote 
Mäuse keine Anzeichen einer Erkrankung zeigen, entwickelten beide homozygoten Gruppen 
Symptomen des Diabetes mellitus, infolge eines Verlusts von β-Zellen und einer 
beeinträchtigten Insulin-Sekretion. Die Behandlung mit  NI 203.26C11 hatte keine keinen 
Einfluss auf die Entwicklung der Krankheitssymptome. Trotzdem muss festgehalten werden, 
dass die Antikörper gut toleriert wurden und keine toxischen oder systemischen Reaktionen 
verursachten. 
 






















1. Type	  2	  diabetes,	  epidemiologic	  overview	  	  
Type	   2	   diabetes	   mellitus	   (T2DM)	   is	   one	   of	   the	   most	   common	   endocrine	   diseases	   diagnosed	   in	  
humans	  worldwide,	  and	  its	  prevalence	  increases	  as	  the	  consequence	  of	  changing	  lifestyle	  and	  eating	  
behavior,	   increasing	  obesity	  and	  decreasing	  physical	  activity	   (S.	  Wilde	  et	  al.,	  2004).	  Epidemiological	  
studies	  estimated	  that	  the	  prevalence	  of	  T2DM	  among	  the	  adult	  population	  worldwide	  reached	  6.4%	  
in	  2010,	  and	  is	  expected	  to	  increase	  up	  to	  7.7%	  in	  2030	  (J.E.	  Shaw,	  2009).	  Not	  only	  the	  prevalence	  of	  
the	  disease	  but	  also	  the	  number	  of	  deaths	  due	  to	  diabetes	  related	  complications	  increases,	  with	  an	  
estimate	  of	  4.8	  million	  deaths	  in	  adults	  attributable	  to	  diabetes	  in	  2012	  (L.	  Guariguata,	  2012).	  Some	  
research	   suggests	   that	   people	   tend	   to	   develop	   diabetes	   at	   an	   earlier	   onset	   which	   may	   be	   a	  
consequence	  of	   increased	   childhood	  obesity.	   People	  with	  early-­‐onset	  diabetes	   tend	   to	   suffer	   from	  
complications	   linked	   to	   the	  disease	   at	   a	   higher	   rate	   and	   are	  more	   likely	   to	   die	   early	   than	  patients	  
developing	  the	  disease	  at	  older	  age	  (D.R.	  Whiting,	  2011).	  T2DM	  has	  not	  only	  serious	  implications	  on	  
health	   and	   lifestyle	   of	   individuals,	   but	   also	   affects	   our	   health	   systems	   and	   the	   economy,	   with	   an	  
estimate	  of	  USD	  471	  billion	  globally	  spent	  on	  the	  treatment	  and	  management	  of	  T2DM	  in	  2012	   (L.	  
Guariguata,	  2012).	  	  
2. Type	  2	  diabetes,	  definition	  and	  pathogenesis	  in	  humans	  
T2DM	  is	  a	  metabolic	  disease	  with	  multiple	  etiologies.	   It	   is	  characterized	  by	  chronic	  hyperglycaemia	  
and	  glucose	  intolerance	  with	  disturbance	  of	  carbohydrate,	  fat	  and	  protein	  metabolism.	  T2DM	  is	  the	  
result	  of	   impaired	   insulin	   secretion,	   insulin	  action,	  or	  both.	  The	  disease	   implies	   long-­‐term	  damage,	  
dysfunction	   and	   failure	   of	   various	   organs.	   Clinically,	   the	   common	   symptoms	   include	  
polyuria/polydypsia,	   weight	   loss	   and	   at	   later	   stages	   blurred	   vision.	   The	   American	   Diabetes	  
Association	   (ADA)	   set	   reference	   values	   for	   the	   clinical	   diagnosis	   of	   human	   non-­‐pregnant	   patients	  
based	   on	   fasting	   glucose	   levels	   and	   oral	   glucose	   tolerance	   tests.	   The	   oral	   glucose	   tolerance	   test	  
consists	  of	   assessing	  glycaemia	  2	  hours	  after	  an	  oral	   glucose	   load	  of	  75g;	   the	   reference	  values	  are	  
shown	  in	  table	  1	  (American	  Diabetes	  Association).	  	  
Clinically	  T2DM	  is	  defined	  and	  can	  be	  diagnosed	  as	  follows:	  	  
Symptoms	   of	   diabetes	   plus	   casual	   plasma	   glucose	   concentration	   ≥200mg/dl	   (11.1mmol/l).	  
Casual	   is	   defined	   as	   any	   time	   of	   day	   without	   regard	   to	   time	   since	   last	   meal.	   The	   classic	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symptoms	  of	  diabetes	  include	  polyuria,	  polydipsia,	  and	  unexplained	  weight	  loss.	  
Or	  
Fasted	  plasma	  glucose	  ≥126mg/dl	   (7.0mmol/l).	  Fasting	   is	  defined	  as	  no	  caloric	   intake	  for	  at	  
least	  8h.	  
Or	  
2	   hours	   postload	   glucose	   ≥200	  mg/dl	   (11.1	   mmol/l)	   during	   an	   oral	   glucose	   tolerance	   test	  
(oGTT).	  The	  test	  should	  be	  performed	  as	  described	  by	  the	  World	  Health	  Organization,	  using	  a	  
glucose	  load	  containing	  the	  equivalent	  of	  75	  g	  anhydrous	  glucose	  dissolved	  in	  water	  
Table	  1:	  Criteria	  for	  the	  diagnosis	  of	  T2DM,	  from	  American	  Diabetes	  Association	  (ADA).	  
The	   two	  major	   features	   of	   the	   pathogenesis	   of	   T2DM	   are	   peripheral	   insulin	   resistance	   and	   β-­‐cell	  
dysfunction;	   in	   most	   instances,	   prevailing	   insulin	   resistance	   leads	   to	   an	   exhaustion	   of	   the	   insulin	  
secretory	  capacity	  of	  pancreatic	  β-­‐cells.	  Together,	  these	  contribute	  to	  impaired	  insulin	  secretion	  and	  
the	  inability	  to	  maintain	  euglycaemia	  without	  glucose-­‐lowering	  therapy.	  	  
3. Overview	  of	  insulin	  synthesis,	  secretion	  and	  action	  
Insulin	   is	   a	   peptide	   hormone	   produced	   by	   the	   β-­‐cells	   of	   the	   pancreas.	   It	   is	   synthesized	   as	  
preproinsulin,	  which	  contains	  a	  24	  amino	  acid	  (-­‐aa)	  residue	  signal	  peptide	  and	  which	  is	  cleaved	  once	  
entering	   the	   endoplasmic	   reticulum	   (ER),	   resulting	   in	   the	   proinsulin	   peptide.	   Once	   folded	   in	   the	  
correct	   conformation,	   proinsulin	   is	   transported	   to	   the	   trans-­‐Golgi	   network	   (TGN)	  where	   immature	  
secretory	  granules	  are	   formed.	  The	  maturation	  of	  proinsulin	   takes	  place	   in	   the	   secretory	  granules,	  
through	  action	  of	  endopeptidases.	  The	  C-­‐peptide,	  a	  31-­‐aa	  residue	  peptide	  is	  released,	  and	  this	  results	  
in	   the	   insulin	  A	  and	  B	  peptide	  chains	  which	  are	   linked	  by	  disulfide	  bonds	  and	   form	  mature	   insulin.	  
Insulin	   is	   stored	   in	   the	   mature	   secretory	   granules	   waiting	   for	   metabolic	   signals	   and	   vagal	   nerve	  
stimulation	  to	  be	  exocytosed	  (G.	  Xu	  et	  al.,	  1998).	  The	  release	  takes	  place	  in	  two	  phases.	  First	  phase	  
occurs	  rapidly	  after	  an	  increase	  in	  blood	  glucose	  levels.	  It	  is	  triggered	  when	  glucose	  enters	  the	  β-­‐cell	  
through	   the	   glucose	   transporter	   2	   (GLUT2).	  After	   glycolysis	   and	  activation	  of	   the	   respiratory	   cycle,	  
the	   rise	   in	   the	   ATP:ADP	   ratio	   leads	   to	   the	   closure	   of	   the	   ATP-­‐sensitive	   potassium	   channel.	   The	  
resulting	   depolarization	   opens	   voltage-­‐gated	   calcium	   channels.	   Increased	   Ca
2+
	   influx	   causes	   the	  
activation	   of	   phospholipase	   C,	  which	   cleaves	   the	  membrane	   phospholipid	   inositol	   4,5-­‐biphosphate	  
into	  inositol	  1,4,5-­‐triphosphate	  (IP3)	  and	  diacylglycerol.	   IP3	  binds	  to	  receptors	  on	  the	  membrane	  of	  
the	  ER,	  opening	   the	   IP3-­‐gated	  channel,	  which	   increases	   further	   the	   intracellular	  Ca
2+	  
concentration	  
and	   allows	   the	   secretion	   of	   previously	   synthesized	   insulin.	   The	   second	   phase	   consists	   in	   a	   slow,	  
sustained	   release	   of	   newly	   formed	   vesicles	   under	   the	   control	   of	   non-­‐glucose	   secretagogues,	   like	  
amino	   acids	   such	   as	   arginine	   or	   leucine,	   parasympathetic	   release	   of	   acetylcholine,	   cholecystokinin	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and	  gastrointestinally	  derived	  incretins	  such	  as	  glucagon-­‐like	  peptide	  (GLP-­‐1)	  and	  glucose-­‐dependent	  
insulinotropic	  peptide	  (GIP)	  (J.	  Bryan	  et	  al.,	  2005).	  	  
Insulin	  binds	  to	  the	  insulin	  receptor	  (IR),	  belonging	  to	  a	  subfamily	  of	  growth	  factor	  receptor	  tyrosine	  
kinases.	   The	   activation	   of	   the	   IR	   initiates	   two	   main	   pathways:	   the	   insulin	   receptor	   substrate	  
(IRS)/phosphatidylinositol	   3-­‐kinase	   (PI3K)	   pathway	   and	   the	   Ras/Mitogen	   activated	   protein	   kinase	  
(MAPK)	  pathway.	  The	  former	  activates	  a	  cascade	  of	  PI3K-­‐dependent	  kinases	  that	  phosphorylate	  and	  
activate	   additional	   serine/threonine	   kinases,	   including	   the	   Akt	   isoforms.	   The	   IRS/PI3K	   pathway	   is	  
involved	   in	   the	   acute	   metabolic	   effects	   of	   insulin,	   such	   as	   glucose	   uptake,	   glycogen	   synthesis,	  
inhibition	   of	   lipolysis	   and	   of	   protein	   degradation	   (D.J.	   Burks	   and	   M.F.	   White,	   2001).	   The	   second	  
pathway	   acts	   through	   the	   formation	   of	   complexes	   between	   the	   exchange	   factor	   Sos	   and	  Grb2.	   In	  
certain	  tissues,	  such	  as	  fat	  or	  skeletal	  muscle,	  this	  plays	  a	  role	  in	  growth	  and	  proliferation	  (Y.	  Kido	  et	  
al.,	  2001).	  	  	  
4. Insulin	  resistance	  
One	   of	   the	   two	   hallmarks	   of	   T2DM	   is	   peripheral	   insulin	   resistance,	   which	   consists	   in	   a	   defect	   of	  
insulin-­‐stimulated	  glucose	  uptake,	  mainly	  in	  adipocytes	  and	  skeletal	  muscle	  cells,	  but	  probably	  also	  in	  
the	  brain	  (D.J.	  Clegg	  et	  al.,	  2011).	  Insulin	  sensitivity	  is	  influenced	  by	  many	  factors	  such	  as	  genetic	  (M.	  
Stumvoll	  et	  al.,	  2002;	  S.	  Sakagashira	  et	  al.,	  1996),	  age	  (M.	  Chen	  et	  al,	  1985),	  acute	  exercise	  (R.J.	  Sigal	  
et	   al.,	   2006;	   S.	   Bordenave	   et	   al.,	   2008),	   physical	   fitness	   (S.E.	   Kahn	   et	   al.,	   1990,	  G.	   Lazarevic	   et	   al.,	  
2006),	  dietary	  nutrients	  (S.	  Egert	  et	  al.,	  2014),	  medication	  such	  as	  steroids	  (J.C.	  Beard	  et	  al.,	  1984;	  S.E.	  
Kahn	  et	  al.,	  1989),	  obesity	  (	  M.C.	  Pouliot	  et	  al.,	  1991;	  A.N.	  Peiris	  et	  al.,	  1989)	  and	  body	  fat	  distribution	  
(B.H.	  Goodpaster	  et	  al.,	  1999;	  M.	  Cnop	  et	  al.,	  2002).	  While	  acute	  exercise	  and	  regular	  physical	  activity	  
have	  a	  positive	  effect	  on	  insulin	  sensitivity,	  advanced	  age,	  obesity	  and	  in	  particular	  abundant	  visceral	  
fat	  contribute	  to	  insulin	  resistance.	  	  
In	  humans,	  skeletal	  muscle	  is	  the	  primary	  site	  of	  insulin-­‐dependent	  glucose	  disposal	  (A.	  Nandi	  et	  al.,	  
2004).	   Resistance	   of	   skeletal	   muscle	   to	   insulin-­‐dependent	   glucose	   uptake	   is	   an	   early	   step	   in	   the	  
development	  of	  T2DM.	  Increased	  fatty	  acid	  concentrations	  elevate	  intramitochondrial	  ratios	  of	  acetyl	  
CoA/CoA	   and	   NADH/NADH+.	   A	   rise	   in	   these	   ratios	   inactivates	   pyruvate	   dehydrogenase,	   increases	  
intracellular	   citrate	   concentration	   and	   inhibits	   phosphofructokinase.	   The	   resulting	   increase	   in	  
glucose-­‐6-­‐phosphate	   inhibits	   hexokinase	   II	   activity,	   which	   leads	   to	   elevated	   intracellular	   glucose	  
concentrations	   and	   a	   resulting	   decrease	   in	   muscle	   glucose	   uptake	   (P.J.	   Randle	   et	   al.,	   1965;	   G.I.	  
Shulman	  et	  al.,	  2000).	  Accumulation	  of	  fatty	  acid	  metabolites	  in	  muscles	  and	  liver,	  either	  caused	  by	  
increased	   delivery	   or	   decreased	   metabolism,	   also	   contributes	   to	   insulin	   resistance	   (G.I.	   Shulman,	  
2000).	   It	   is	   thought	   that	   increasing	   intracellular	   fatty	   acid	  metabolites,	   such	  as	  diacylglycerol,	   fatty	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acyl	   CoA	   or	   ceramides	   activate	   a	   serine/threonine	   kinase	   cascade,	   leading	   to	   phosphorylation	   of	  
serine/threonine	   sites	   on	   insulin	   receptor	   substrates	   (IRS).	   Serine-­‐phosphorylated	   forms	   of	   these	  
proteins	   cannot	   associate	   with	   or	   activate	   PI3K,	   resulting	   in	   a	   decreased	   activation	   of	   glucose	  
transport	  (G.I.	  Shulman,	  2000).	  
5. β-­‐cell	  dysfunction	  
Under	   normal	   circumstances,	   the	   secretion	   of	   insulin	   by	   β-­‐cells	   is	   modulated	   by	   a	   number	   of	  
variables,	  including	  the	  route	  of	  administration	  and	  concentration	  of	  glucose	  (M.	  Perley	  et	  al.,	  1967;	  
J.D.	   Bagdade	   et	   al.,	   1967;	  W.K.	  Ward	   et	   al.,	   1984),	   the	   nature	   and	   quantity	   of	   secretagogues	   and	  
systemic	   insulin	   sensitivity.	   In	   the	   early	   stages	   of	   T2DM,	   although	   acute	   glucose-­‐induced	   insulin	  
secretion	   is	   impaired,	   stores	   of	   insulin	   are	   still	   preserved,	   indicating	   a	   failure	   in	   insulin	   secretory	  
mechanisms;	  this	  may	  be	  due	  to	  defects	  in	  the	  first	  phase	  of	  insulin	  release	  (C.G.	  Weir	  et	  al.,	  2001).	  
When	   decompensation	   occurs,	   the	   synthesis	   and	   secretion	   of	   insulin	   are	   impaired.	   In	   fact,	   insulin	  
gene	   expression	   decreases	   while	   the	   expression	   of	   other	   metabolites	   (such	   as	   LDH,	   hexokinase,	  
glucose-­‐6-­‐phosphatase,	  and	  the	  transcription	  factor	  c-­‐Myc)	  and	  stress	  genes	  is	  increased	  (G.C.	  Weir	  
et	  al.,	  2000).	  Hence,	  in	  T2DM	  patients,	  β-­‐cell	  mass	  and	  function	  are	  eventually	  compromised	  and	  fail	  
to	  compensate	  for	  insulin	  resistance.	  	  
Although	   the	   nature	   of	   the	   primary	   β-­‐cell	   defect	   stays	   elusive,	   once	   established	   chronic	  
hyperglycemia	   and	   hyperlipidemia	   seem	   to	   exert	   deleterious	   effects	   on	   β-­‐cell	   function	   (R.P.	  
Robertson	  et	  al.,	  2000).	  Hyperglycemia	  contributes	  to	  glucose	  desensitization,	  β-­‐cell	  exhaustion	  and	  
glucotoxic	  β-­‐cell	  loss	  (E.	  Zini	  et	  al.,	  2010).	  Increased	  expression	  of	  the	  protooncogene	  c-­‐Myc	  has	  been	  
postulated	  to	  reflect	  a	  loss	  of	  differentiation	  of	  β-­‐cells	  exposed	  to	  elevated	  glucose	  (J.C.	  Jonas	  et	  al.,	  
1999).	  The	  mechanisms	  of	  glucotoxicity	  may	  also	  involve	  activation	  of	  chronic	  oxidative	  stress,	  which	  
impairs	   the	   transcription	   of	   the	   insulin	   gene	   and	  may	   lead	   to	   apoptosis	   (Y.	   Tajiri	   et	   al.,	   1997;	   T.A.	  
Matsuoka	  et	  al.,	  1997;	  Y.	  Ihara	  et	  al.,	  1999).	  Structural	  damages	  can	  also	  be	  found	  and	  contribute	  to	  
β-­‐cell	  dysfunction.	  	  
6. Overview	  of	  IAPP	  action	  	  
Islet	  amyloid	  polypeptide	  (IAPP),	  also	  called	  amylin,	  is	  a	  37-­‐aa	  peptide	  that	  belongs	  to	  the	  calcitonin	  
peptide	  family.	  It	  is	  initially	  expressed	  as	  an	  89-­‐aa	  preproprotein	  that	  includes	  a	  22-­‐aa	  signal	  peptide	  
and	   two	   short	   flanking	  peptides.	   IAAP	   is	   processed	   in	   a	   similar	  way	   as	   proinsulin;	   the	   22-­‐aa	   signal	  
peptide	   is	   removed	   in	   the	   ER.	   The	   resulting	   proIAPP	   is	   then	   transformed	   to	   IAPP	   in	   the	   Golgi	  
apparatus	   and	   secretory	   vesicles,	   after	   proteolysis	   and	   posttranslational	   modification.	   After	   a	  
disulfide	  bond	  is	  formed	  between	  cystein	  residues	  2	  and	  7,	  the	  transformation	  from	  proIAPP	  to	  the	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biologically	  active	  IAPP	  is	  completed	  (see	  Fig.	  1;	  J.	  Wang	  et	  al.,	  2001;	  S.P.	  Smeekens	  et	  al.,	  1992;	  H.W.	  
Davidson	  et	  al.,	  1987;	  L.	  Marzban	  et	  al.,	  2004).	  	  
IAPP	  is	  stored	  in	  the	  halo	  region	  of	  the	  secretory	  granules	  of	  the	  β-­‐cell	  (P.	  Westermark	  et	  al.,	  1996)	  
and	  is	  co-­‐secreted	  with	  insulin.	  Both	  IAPP	  and	  insulin	  genes	  contain	  similar	  promoter	  elements	  and	  
are	  regulated	  by	  transcription	  factors	  such	  as	  pancreatic	  and	  duodenal	  homebox	  1	  (PDX1,	  M.	  German	  
et	  al.,	  1995;	  H.	  Ohlsson	  et	  al.,	  1993;	  H.	  Watada	  et	  al.,	  1996).	  As	  a	  circulating	  hormone,	  IAPP	  plays	  an	  
important	   role	   in	  energy	  homeostasis;	   it	   reduces	  energy	   intake,	   increases	  energy	  expenditure,	  and	  
inhibits	   gastric	   emptying	   and	   postprandial	   glucagon	   secretion	   (T.A.	   Lutz,	   2013);	   all	   these	   functions	  
seem	  to	  depend	  on	  a	  hormonal	  function	  in	  the	  central	  nervous	  system	  (G.	  Christopoulos	  et	  al.,	  1995;	  
T.A.	  Lutz,	  2013).	  Binding	  sites	  for	  IAPP	  have	  been	  described	  in	  several	  locations	  in	  the	  brain,	  notably	  
in	   the	   area	   postrema	   (AP)	   and	   in	   the	   nucleus	   accumbens.	   IAPP’s	   effect	   on	   eating	   depends	   on	   the	  
promotion	   of	   meal-­‐ending	   satiation	   (T.A.	   Lutz,	   2013;	   T.A	   Lutz,	   2006;	   T.A.	   Lutz	   et	   al.,	   1995).	   As	  
mentioned,	   IAPP	   shares	   structural	   similarity	   with	   calcitonin.	   Accordingly,	   it	   has	   been	   shown	   that	  
amylin	   can	   also	   inhibit	   osteoclastic	   activity	   and	   therefore,	   it	   may	   have	   a	   physiological	   role	   in	   the	  















Fig.	  1:	  A.	  –Amino	  acid	  sequence	  of	  human	  proIAPP.	  Cleavage	  sites	  for	  prohormone	  convertase	  2	  (PC2	  
at	  the	  NH2	  terminus)	  and	  prohormone	  convertase	  1/3	  (PC1/3	  at	  the	  COOH	  terminus)	  are	  indicated	  by	  
arrows.	  KR	  residues	  (in	  blue)	  are	  removed	  by	  the	  carboxipeptidase	  E	  (CPE).	  
B.	   –Structure	   of	  mature	   human	   IAPP	  with	   intramolecular	   S-­‐S	   bond	   between	   residues	   2-­‐7	   and	   the	  
amidated	  COOH	  terminus	  (adapted	  from	  P.	  Westermark	  et	  al.,	  2011).	  
	  
7. Heterogeneity	  of	  IAPP	  and	  amyloidogenesis	  
In	   general,	   the	   aa	   sequence	   of	   IAPP	   is	   strongly	   conserved	   among	  mammalian	   species.	   Pancreatic	  
amyloid	   deposition	   derived	   from	   IAPP	   precipitation,	   however,	   has	   been	   shown	   only	   in	   humans’,	  
other	  primates’	   and	   cats’	   pancreatic	   islets.	   These	   species	   express	   an	   amyloidogenic	   region	  of	   IAPP	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that	  is	  essential	  for	  amyloid	  formation	  and	  toxicity.	  Amyloid	  is	  a	  generic	  term	  that	  refers	  to	  specific	  
protein	  aggregations	  in	  which	  the	  molecules	  are	  present	  in	  β-­‐sheet	  conformation	  and	  bound	  to	  each	  
other,	  and	  which	  leads	  to	  a	  typical	  light	  microscopic	  “amyloid”	  appearance.	  
In	   the	   case	  of	   IAPP,	   amyloidogenesis	   seems	   to	  be	   associated	  with	   the	  heterogeneity	  of	   the	   amino	  
acid	  residues	  20-­‐29	  in	  the	  IAPP	  sequence.	   In	  species	  where	  pancreatic	  amyloid	  deposition	  does	  not	  
occur,	  like	  mouse	  or	  rat,	  one	  or	  more	  proline	  residues	  can	  be	  found	  in	  this	  region.	  The	  substitution	  of	  
proline	   residues	   at	   either	   position	   22,	   24	   or	   between	   26	   and	   28	   leads	   to	   a	   drastic	   reduction	   of	  
amyloid	   formation	   (see	   Fig.	   2).	   It	   is	   thought	   that	   the	   presence	   of	   proline	   residues	   disrupts	   the	  
ordered	   structure,	   like	   the	   β-­‐sheet	   conformation,	   and	   subsequently	   inhibits	   amyloid	   aggregation	  
(D.F.	  Moriarty	  et	  al.,	  1999;	  C.	  Betsholtz	  et	  al.,	  1989;	  A.V.	  Matveyenko	  et	  al.,	  2006;	  C.	  Wu	  et	  al.,	  2013).	  
	  
Fig	   2:	   Different	   sequence	   in	   amino	   acid	   residues	   20-­‐29	   in	   human,	   monkey,	   cat,	   mouse	   and	   rat	  
(adapted	  from	  A.V.	  Matveyenko	  et	  al.,	  2006).	  
	  
8. Amyloid	  aggregation	  	  
Generally	  speaking,	  amyloid	  formation	  is	  similar	  to	  the	  build-­‐up	  of	  crystals	  from	  salts.	  Starting	  from	  
an	  initial	  nucleation	  center,	  crystallization	  continues	  to	  build	  larger	  conglomerates.	  Similarly,	  the	  first	  
step	  in	  fibril	  formation	  is	  called	  “the	  nucleation	  phase”,	   in	  which	  monomer	  peptides	  start	  to	  unfold	  
and	   form	  a	   core.	   The	   second	  phase	   consists	   in	   the	  elongation	  of	   amyloid	   fibrils,	  while	   in	   the	   third	  
phase,	   fibrils	   formation	   reaches	  a	   steady	   state	  and	   the	   fibrillar	  mass	   is	   constant	   (A.S.	  Cohen	  et	  al.,	  
1959).	  
Monomeric	  IAPP	  is	  normally	  soluble	  and	  natively	  unfolded.	  It	  is	  believed	  that	  IAPP	  is	  protected	  from	  
aggregation	   by	   interaction	   with	   other	   components	   within	   the	   secretory	   vesicles	   like	   insulin,	   pro-­‐
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insulin	  or	  their	  processing	  intermediates	  (P.	  Westermark	  et	  al.,	  1996).	  It	  seems	  that	  small	  changes	  in	  
the	   concentration	   of	   IAPP	   in	   comparison	  with	   other	   halo	   components	   can	   initiate	   the	   aggregation	  
and	   formation	  of	   fibrils	   under	   certain	   conditions	   (J.F.	   Paulsson	  et	   al.,	   2006).	  When	   fibril	   formation	  
begins,	  the	  molecules	  in	  β-­‐sheet	  conformation	  are	  bound	  to	  each	  other,	  predominantly	  by	  hydrogen	  
bounds.	  This	  β-­‐sheet	  forms	  thin	  and	  stable	  layers	  in	  which	  the	  β-­‐strands	  are	  oriented	  perpendicular	  
to	  the	  fibril	  axis.	  	  
Fibril	   deposition	   has	   originally	   been	   thought	   to	   be	   mostly	   extracellular.	   However,	   it	   has	   been	  
demonstrated	   that	   amyloid	   formation	   may	   actually	   begin	   within	   the	   cell	   (E.T.A.S.	   Jaikaran	   et	   al.,	  
2001;	   J.	   Janson	  et	  al.,	  1996;	   J.F.	  Paulsson	  et	  al.,	  2006;	  G.T.	  Westermark	  et	  al.,	  2000;	  K.	  Yagui	  et	  al.,	  
1995).	   Similarly,	   studies	   in	   insulinoma	   which	   may	   also	   be	   associated	   with	   IAPP-­‐derived	   amyloid	  
formation,	   showed	   that	   fibrillogenesis	   initiates	   intracellularly	   (T.D.	  O’Brien	  et	  al.,	  1994).	   Further,	   in	  
addition	  to	  mature	  IAPP,	  proIAPP	  and	  its	  intermediates	  may	  also	  be	  amyloidogenic	  and	  hence	  may	  be	  
the	  starting	  point	  of	  the	  aggregation	  (G.T.	  Westermark	  et	  al.,	  2000).	  
No	  precise	   localization	  of	   the	  aggregates	  within	   the	  cells	  has	  been	  demonstrated	  yet.	   In	   studies	   in	  
baboons,	   amyloid	   deposits	   were	   observed	   in	   the	   cytoplasm	   as	   well	   as	   bound	   to	   the	   outer	   β-­‐cell	  
membrane	  (R.	  Guardado-­‐Mendoza	  et	  al.,	  2009).	  In	  other	  studies,	  where	  islets	  from	  diabetic	  patients	  
were	  transplanted	  in	  nude	  mice	  or	  cultured	  in	  vitro,	  early	  amyloid	  formed	  an	  intracellular	  network,	  
suggesting	  its	  presence	  in	  the	  ER	  (J.F.	  Paulsson	  et	  al.,	  2006;	  P.	  Westermark	  et	  al.,	  1995)	  but	  also	  in	  the	  
Golgi	  and	  secretory	  vesicles	  (K.	  Yagui	  et	  al.,	  1995).	  Finally,	  prolonged	  hyperglycemia	  per	  se	  may	  lead	  
to	  a	  higher	  concentration	  of	  proIAPP	  within	  the	  β-­‐cells	  (X.	  Hou	  et	  al.,	  1999).	  This	  may	  create	  a	  core	  
for	   further	   aggregation,	   ultimately	   leading	   to	   the	   death	   of	   the	   cell	   and	   deposition	   of	   extracellular	  
amyloid	  (J.F.	  Paulsson	  et	  al.,	  2005).	  	  
9. Cytotoxic	  effect	  of	  IAPP	  oligomers	  
Islet	  amyloid	  formation	  is	  a	  striking	  abnormality	  of	  human	  T2DM	  and	  can	  be	  found	  in	  more	  than	  90%	  
of	   T2DM	   patients	   (A.	   Clark	   and	   M.R.	   Nilsson,	   2004).	   Similarly,	   islet	   amyloid	   is	   a	   very	   prominent	  
feature	  in	  diabetic	  cats	  (T.A.	  Lutz	  et	  al.,	  2014;	  T.	  O’Brien	  et	  al.,	  1993;	  A.M.	  Herndon	  et	  al,	  2014).	  
The	  toxicity	  of	  amyloid	  deposition	  or	  oligomers	  may	  depend	  on	  the	  action	  of	  different	  mechanisms	  
that	  act	  together	  intra-­‐	  and	  extracellulary.	  	  
9.a.	  ER	  stress	  and	  unfolded	  protein	  response	  (UPR)	  
ER	   stress	   is	   an	   important	   feature	   in	   IAPP-­‐related	   β-­‐cell	   toxicity	   and	   therefore	   T2DM	   pathology.	  
Peripheral	   insulin	   resistance	   triggers	   β-­‐cells	   to	   produce	  more	   insulin	   in	   parallel	   with	   an	   increased	  
synthesis	  of	  IAPP.	  As	  these	  proteins	  are	  destined	  for	  exocytosis,	  they	  are	  transported	  through	  the	  ER	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and	  trans-­‐Golgi	  complex	  and	  stored	  in	  secretory	  granules	  before	  secretion.	  In	  the	  tubular	  system	  of	  
the	  ER,	  proteins	  fold	  into	  their	  native	  structure	  and	  undergo	  posttranslational	  modifications.	  	  
ER	  stress	  is	  characterized	  by	  the	  unfolded	  protein	  response	  (UPR),	  which	  is	  induced	  to	  cope	  with	  an	  
increase	  in	  proteins	  synthesis	  or	  obstruction	  in	  the	  ER-­‐Golgi	  transport	  (A.M.	  Preston	  et	  al.,	  2009).	  This	  
may	   e.g.	   happen	   during	   increased	   IAPP	   synthesis	   in	   early	   phases	   of	   T2DM.	   UPR	   consists	   in	   the	  
upregulation	   of	   ER-­‐located	   chaperones	   to	   assist	   in	   the	   folding	   of	   proteins	   prone	   to	   aggregation.	  
Misfolded	  proteins	  are	  then	  transported	  to	  the	  ubiquitin-­‐proteasome	  system	  for	  degradation.	  If	  the	  
homeostasis	  cannot	  be	  reestablished,	  apoptosis	  is	  induced	  (E.L.	  Davenport	  et	  al.,	  2008;	  S.J.	  Marciniak	  
et	  al.,	  2006;	  S.	  Oyadomari	  et	  al.,	  2002).	  	  
9b.	  Reactive	  oxygen	  species	  (ROS)	  
The	  overexpression	  of	  ProIAPP	  or	   IAPP	   in	  early	  phases	  of	  T2DM	  characterized	  by	  β-­‐cell	   stimulation	  
with	   increased	   insulin	   and	   IAPP	   transcription	  may	   lead	   to	   the	   formation	   of	   toxic	   oligomers.	   These	  
oligomers	   may	   enter	   the	   cytosol	   and	   disrupt	   the	   membrane	   of	   organelles	   such	   as	   mitochondria	  
resulting	   in	   increased	   cellular	   oxidative	   stress	   and	   the	   formation	  of	   reactive	   oxygen	   species	   (ROS).	  
Increased	   ROS	   levels	  may	   ultimately	   lead	   to	   significant	   damages	   to	   cell	   structures	   (T.	   Gurlo	   et	   al.,	  
2010;	  J.K.	  Parks	  et	  al.,	  2001;	  R.	  Scherz-­‐Shouval	  et	  al.,	  2007).	  	  	  
9c.	  Autophagy	  
	  Accumulation	  of	  fibrillar	  material	  in	  the	  halo	  region	  of	  secretory	  vesicles	  may	  lead	  to	  a	  disruption	  of	  
the	  vesicles	  and	   result	   in	   the	   release	  of	   fibrillar	  material	   into	   the	  cytosol.	  Because	   the	  proteasome	  
pathway	  can	  degrade	  misfolded	  single	  proteins	  but	  not	  their	  aggregates,	  the	  latter	  will	  be	  dissolved	  
by	   the	   autophagy	   process.	   Autophagy	   is	   a	   well-­‐preserved	   catabolic	   process	   that	   is	   active	   in	  
degradation	   and	   recycling	   of	   misfolded	   proteins,	   excess	   or	   defective	   organelles.	   Autophagosomes	  
fuse	   with	   lysosomes,	   forming	   autophagolysosomes.	   Eventually,	   their	   maturation	   is	   hampered,	  
causing	   accumulation	   of	  material	   in	   autophagic	   vacuoles,	   disturbing	   intracellular	   cell	   transport	   (F.	  
Shang	  et	  al.,	  1997;	  E.L.	  Davenport	  et	  al.,	  2008;	  S.J.	  Marciniak	  et	  al.,	  2006;	  M.	  Schröder,	  2008).	  Such	  a	  
process	  with	  an	  intracellular	  accumulation	  of	  autophagolysosomes	  has	  been	  suggested	  to	  induce	  cell	  
death	  in	  pancreatic	  β-­‐cells	  (W.	  Bursch	  et	  al.,	  2000).	  
9d.	  Cell	  membrane	  damages	  
The	  direct	  toxicity	  of	  amyloid	  for	  the	  cell	  membranes	  is	  thought	  to	  be	  mediated	  by	  two	  pathways.	  On	  
one	  hand,	  toxic	  oligomers	  can	  develop	  and	  be	   inserted	   into	  the	  membrane	  and	  act	   like	   ion-­‐leaking	  
pores	  (M.	  Kawahara	  et	  al.,	  2000).	  On	  the	  other	  hand,	  misfolded	  monomers	  or	  oligomers	  can	  interact	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with	  membrane	  structures.	  As	  these	  fibrils	  may	  continue	  to	  grow,	  they	  can	  lead	  to	  invaginations	  and	  
mechanical	  disruption	  of	  the	  cell	  membrane,	  as	  depicted	  in	  Fig.	  3	  (P.E.S.	  Smith	  et	  al.,	  2009).	  	  
Fig.	  3:	  Scheme	  representing	  potential	  cell	  toxicity	  mechanisms	  linked	  to	  amyloid	  formation	  in	  T2DM	  
(adapted	  from	  P.	  Westermark	  et	  al.,	  2011).	  
	  
9e.	  Other	  cytotoxic	  effects	  
Finally,	   aggregated	   IAPP	   may	   activate	   the	   inflammasome,	   a	   multiprotein	   oligomer	   expressed	   in	  
myeloid	  cells	  and	  components	  of	  the	  innate	  immune	  system,	  to	  produce	  interleukine-­‐1β,	  (IL-­‐1β).	  This	  
may	  also	   lead	   to	  β-­‐cell	   death	   (M.Y.	  Donath,	   2011;	  M.Y.	  Donath,	   2013;	   S.L.	  Masters	  et	   al.,	   2010;	  C.	  
Westwell-­‐Roper	   et	   al.,	   2011).	   IL-­‐1β	   receptor	   antagonists	   have	   been	   shown	   to	   be	   beneficial	   in	   the	  
treatment	  of	  T2DM	  (M.Y.	  Donath,	  2013).	  Finally	  human	   IAPP	  can	  also	  directly	   induce	  apoptosis	  via	  
activation	   of	   acid	   sphingomyelinase	   which	   produces	   ceramide	   and	   which	   in	   turn	   is	   involved	   in	  
programmed	  cell	  death	  (Y.	  Zhang	  et	  al.,	  2009).	  	  
10. Islet	  amyloid	  deposition	  and	  T2DM	  
Studies	   in	   several	   animal	   species	   with	   naturally	   occurring	   IAPP	   derived-­‐amyloid	   and	   in	   transgenic	  
animals	  expressing	  human	  IAPP	  demonstrated	  that	  islet	  amyloid	  formation	  plays	  a	  key	  role	  in	  β-­‐cell	  
apoptosis	  and	  dysfunction	  (A.E.	  Butler	  et	  al.,	  2004;	  E.J.P.	  De	  Koning	  et	  al.,	  1993;	  C.F.J.	  Howard,	  1978;	  
C.F.J.	  Howard,	  1986;	  K.H.	  Johnson	  et	  al.,	  1989;	  O’Brien	  et	  al.,	  1985;	  O’Brien	  et	  al.,	  1986;	  R.	  Guardado-­‐
Mendoza	   et	   al.,	   2009).	   A	   reduction	   of	   islet	   volume	   due	   to	   a	   decrease	   in	   β-­‐cell	   mass	   has	   been	  
associated	  with	   increased	   islet	  amyloid	  deposits	   (F.	  Wang	  et	  al.,	  2001;	  P.	  Westermark	  et	  al.,	  1978).	  
Interestingly,	   the	   extent	   of	   the	   amyloid	   deposition	   in	   diabetic	   humans	   can	   vary	   from	   very	   little	   to	  
80%	   of	   the	   islets	   (A.	   Clark	   and	   M.R.	   Nilsson,	   2004).	   This	   indicates	   that	   in	   humans,	   islet	   amyloid	  
formation	  may	  rather	  be	  a	  result	  of	  diabetes-­‐related	  pathologies	  than	  a	  single	  etiological	  factor.	  On	  
the	   other	   hand,	   it	   has	   been	   shown	   that	   the	   progressive	   increase	   in	   small	   perivascular	   amyloid	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deposits	  correlates	  with	  progressive	  β-­‐cell	  dysfunction	  in	  rodent	  models	  as	  well	  as	  in	  obese	  cats	  and	  
monkeys	  (A.	  Clark	  and	  M.R.	  Nilsson,	  2004).	  Similar	  correlations	  have	  also	  been	  observed	  in	  humans,	  
where	  progressive	  β-­‐cell	  destruction	  was	  associated	  with	  severe	  islets	  damage	  and	  increased	  insulin	  
requirements	   to	   control	   glycaemia	   (A.	   Clark	   and	   M.R.	   Nilsson,	   2004).	   Therefore,	   whether	   IAPP	  
deposition	  is	  a	  primary	  cause	  or	  a	  consequence	  of	  T2DM	  still	  remains	  somewhat	  controversial.	  	  
11. Strategies	  against	  amyloid	  formation	  
Several	  strategies	  to	  block	  various	  key	  steps	  in	  amyloidogenesis	  are	  currently	  pursued.	  One	  strategy	  
consists	  in	  the	  inhibition	  of	  the	  expression	  of	  the	  amyloidogenic	  protein	  itself,	  for	  example	  by	  using	  
anti-­‐sense	  DNA.	  Although	  this	  approach	  shows	  promising	  results	   in	  vitro,	  blocking	  a	  natural	  protein	  
or	  peptide	   that	  plays	   important	  biological	   functions	  might	  not	  be	  safe	   in	  vivo	   (F.G.	  De	  Felice	  et	  al.,	  
2002;	  K.A.	  Conway	  et	  al.,	  2003)	  and	  it	  may	  be	  difficult	  to	  maintain	  the	  effect	  over	  extended	  periods.	  
In	   fact,	   the	   lack	   of	   circulating	   IAPP	   seems	   to	   be	   responsible	   for	   pathologically	   accelerated	   gastric	  
emptying	   and	   exaggerated	   postprandial	   release	   of	   glucagon	   that	   may	   contribute	   to	   postprandial	  
hyperglycemia,	  as	  shown	  in	  patients	  suffering	  from	  type	  1	  diabetes	  (H.J.	  Woerle	  et	  al.,	  2008)	  but	  also	  
T2DM.	  Another	  strategy	  using	  small	  organic	   ligands,	  such	  as	  N-­‐phenyl	  phenoxazines	  and	  flufenamic	  
acid	  derivates,	  aims	  at	  stabilizing	  the	  native	  form	  of	  the	  amyloidogenic	  peptide	  (M.G.	  McCammon	  et	  
al,	  2002).	  	  
In	  other	  amyloid-­‐associated	  diseases,	  such	  as	  Alzheimer	  disease	  (AD),	  the	  precursor	  protein	  has	  to	  be	  
cleaved	  by	  enzymes	  to	  form	  amyloidogenic	  peptides.	  Drugs	  targeting	  the	  inhibition	  of	  these	  enzymes	  
are	   interesting	   targets	   in	   the	   management	   or	   prevention	   of	   amyloid	   deposition.	   However,	   this	  
approach	   would	   not	   be	   helpful	   in	   the	   case	   of	   T2DM	   because	   it	   is	   the	   full	   length	   peptide	   that	   is	  
amyloidogenic	  (C.	  Haass	  and	  B.	  De	  Strooper	  et	  al.,	  1999).	  	  
Other	   treatments	   designed	   to	   inhibit	   the	   aggregation	   of	   proteins	   either	   by	   using	   small	   ligands	   or	  
indirectly	  by	  immunization	  are	  under	  consideration.	  The	  latter	  treatment	  strategy	  may	  not	  be	  able	  to	  
prevent	  the	  initial	  formation	  of	  oligomers	  or	  insoluble	  fibers	  and	  may	  be	  less	  effective	  than	  strategies	  
targeting	  the	  steps	  prior	  to	  protein	  aggregation.	  Nonetheless,	  the	  inhibition	  of	  the	  aggregation	  is	  an	  
attractive	  therapeutic	  strategy	  as	  it	   is	  not	  supposed	  to	  interfere	  with	  the	  natural	  biological	  function	  
of	  the	  underlying	  peptide	  (J.M.	  Mason	  et	  al.,	  2003).	  	  
	  
12.	  Immunotherapy	  against	  toxic	  aggregates	  of	  IAPP	  	  
Immunotherapy	   against	   amyloid	   deposition	   has	   been	   successfully	   developed	   for	   several	   brain	  
diseases	   involving	   protein	   aggregation	   such	   as	   Alzheimer’s	   disease,	   Parkinson’s	   disease,	   and	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amyotrophic	   lateral	   sclerosis	   (H.	   Jindal	  et	  al.,	  2014;	  D.R.	  Shprecher	  et	  al.,	  2013;	  K.	  Marciniuk	  et	  al.,	  
2013).	  Alzheimer’s	  disease	  (AD)	  shares	  several	  pathophysiological	  features	  with	  T2DM	  that	  underlie	  
the	  respective	  degenerative	  developments	  of	  neurons	  or	  β-­‐cells,	  respectively	  (L.	  Li	  and	  C.	  Hölscher,	  
2007).	   These	   include	   aging-­‐related	   processes,	   high	   cholesterol	   levels,	   metabolic	   disorders	   and	   β-­‐
amyloid	  aggregation.	  Besides	  the	  fact	  that	  both	  diseases	  show	  disturbances	  in	  insulin,	  insulin	  growth	  
factors	  and	  transforming	  growth	  factor	  signaling,	  the	  misfolding	  of	  proteins	  plays	  an	  important	  role	  
in	  AD	  as	  well	   as	   in	   T2DM	   (M.	  Romano	  et	   al.,	   2003;	   I.	   Tesseur	   et	   al.,	   2006;	   C.	  Hölscher,	   2005,	  D.H.	  
Small	  and	  R.	  Cappai,	  2006;	  A.	  Clark	  et	  al.	  1988;	  S.	  Mohanty	  et	  al.,	  2005;	  H.D.	  Venters	  et	  al.,	  2001).	  
Thus,	  at	  the	  structural	  level,	  amyloid	  polypeptide	  (APP)	  derived	  amyloid	  deposition	  in	  AD	  shares	  90%	  
similarities	  with	  IAPP	  derived	  amyloid	  found	  in	  T2DM	  (J.	  Janson	  et	  al.,	  2004).	  	  
In	  2000,	  Games	  et	  al.	  published	  a	  study	  on	  the	  effects	  of	  intraperitoneal	  administration	  of	  antibodies	  
against	   Aβ-­‐plaques	   in	   a	   mouse	   model	   for	   Alzheimer’s	   disease.	   PDAPP	   mice	   were	   used	   which	   are	  
transgenic	  for	  an	  amyloid	  β	  precursor	  protein	  mini-­‐gene	  driven	  by	  a	  platelet	  growth	  factor	  promoter	  
(D.	  Games	  et	  al.,	  2000).	  These	  mice	  overproduce	  the	  highly	  amyloidogenic	  Aβ1-­‐42	  peptide	  relative	  to	  
other	   Aβ	   peptides	   and	   show	   many	   of	   the	   pathological	   features	   of	   Alzheimer	   disease,	   including	  
extensive	   deposition	   of	   extracellular	   amyloid	   plaques	   in	   the	   cortex	   and	   hippocampus,	   astrocytosis	  
and	  neural	  dystrophy	  (D.	  Games	  et	  al.,	  1995;	  E.	  Masliah	  et	  al.,	  1996).	  Monoclonal	  antibodies	  against	  
Aβ	  plaque	  bound	  to	  amyloid	  aggregates.	  Injected	  antibodies	  were	  found	  in	  the	  brain,	  indicating	  that	  
the	  antibodies	  were	  able	  to	  cross	  the	  blood-­‐brain	  barrier	  and	  to	  enter	  the	  central	  nervous	  system	  to	  
reach	  plaques.	  Interestingly,	  the	  antibodies	  reduced	  the	  plaque	  burden	  by	  about	  80%	  in	  the	  cortex.	  
The	  passive	  immunization	  with	  exogenous	  antibodies	  against	  Aβ	  did	  not	  result	  in	  a	  T-­‐cell	  proliferative	  
response	   to	   Aβ.	   Ex	   vivo	   assays	   with	   sections	   of	   brains	   from	   PDAPP	   mice	   or	   deceased	   Alzheimer	  
patients	  indicated	  that	  the	  antibodies	  triggered	  microglial	  cells	  to	  clear	  plaques	  through	  Fc	  receptor-­‐
mediated	   phagocytosis	   and	   subsequent	   peptide	   digestion.	   A	   T-­‐cell	   response	   did	   not	   seem	   to	   be	  
required	   for	  amyloid	  plaque	  clearance;	   in	  other	  words,	   the	  antibodies	  appeared	   to	  be	  sufficient	   to	  
decrease	   amyloid	   deposition	   in	   PDAPP	   mice.	   In	   another	   study	   (C.	   Hock	   et	   al.,	   2003),	   active	  
immunization	   was	   tested	   in	   human	   patients	   suffering	   from	  mild	   to	  moderate	   forms	   of	   Alzheimer	  
disease.	  These	  patients	  received	  active	  prime	  and	  booster	  immunizations	  with	  preaggregated	  Aβ1-­‐42	  
or	   placebo,	   in	   a	   double-­‐blind,	   randomized	   study	   design.	   The	   patients	   who	   generated	   antibodies	  
specifically	   recognizing	   β-­‐amyloid	   plaques	   performed	   markedly	   better	   on	   the	   Mini	   Mental	   State	  
Examination	  (MMSE)	  and	  had	  significantly	  better	  Disability	  Assessment	  for	  Dementia	  (DAD)	  rating.	  	  	  
These	   clinical	   studies	   suggested	   that	   immunization	   against	   toxic	   oligomers	   may	   have	   beneficial	  
effects	  in	  slowing	  the	  clinical	  and	  the	  cognitive	  decline	  of	  patients	  with	  AD.	  Similar	  approaches	  may	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therefore	  be	  promising	   in	   the	   treatment	  of	  other	  diseases	  associated	  with	  amyloid	  aggregation,	   in	  
particular	  T2DM.	  	  
13.	  Animal	  models	  of	  Type	  2	  Diabetes	  
To	  study	  the	  pathophysiology	  of	  pancreatic	  dysfunction	  in	  T2DM,	  longitudinal	  studies	  of	  the	  pancreas	  
morphology	   in	   humans	   are	   not	   possible.	   Usually,	   human	   tissue	   is	   only	   available	   at	   the	   time	   of	  
autopsy	   or	   during	   surgical	   resection	   of	   pancreatic	   cancers.	   This	   may	   lead	   to	   problems	   like	   post	  
mortem	  autolysis	  or	  altered	  islet	  function	  and	  anatomy	  in	  the	  case	  of	  cancer	  (M.	  Shimizu	  et	  al.	  1990;	  
P.	  Fogar	  et	  al.,	  1994).	  The	  study	  of	  species	  like	  non-­‐human	  primates	  and	  cats	  that	  naturally	  express	  
amyloidogenic	   IAPP	  and	  that	  may	  spontaneously	  develop	  diabetes	   is	  complicated	  by	  ethical	   issues,	  
by	  the	  relatively	  slow	  progression	  of	  the	  natural	  disease,	  by	  the	  small	  and	  unpredictable	  number	  of	  
individuals	  who	  may	  actually	  suffer	  from	  the	  disease	  (Howard	  et	  al.,	  1986;	  T.D.	  O’Brien	  et	  al.,	  1993)	  
and	  by	   the	  high	  housing	  and	  maintenance	  costs	  of	  experimental	   animals	   (A.V.	  Matveyenko	  et	  P.C.	  
Butler,	  2006).	  	  
Traditionally,	  some	  of	  the	  most	  common	  rodent	  models	  used	  for	  longitudinal	  studies	  to	  study	  some	  
aspects	  of	  T2DM	  were	  the	  db/db	  mouse	  and	  the	  diabetes-­‐prone	  Zucker	  diabetic	  fatty	  rat	  (ZDF).	  Both	  
models	  are	  characterized	  by	  mutations	  of	  the	  leptin	  receptor	  (H.	  Chen	  et	  al.,	  1996;	  M.S.	  Philips	  et	  al.,	  
1996).	  Ob/ob	  mice,	  carrying	  a	  mutation	  in	  the	  leptin	  gene,	  were	  also	  used	  (M.A.	  Pelleymounter	  et	  al.,	  
1995).	  Both	  receptor-­‐deficient	  and	  leptin	  deficient	  models	  develop	  severe	  obesity	  with	  sudden	  onset	  
of	  hyperglycaemia	  (F.	  Kawasaki	  et	  al.,	  2005;	  Y.	  Lee	  et	  al.,	  1994;	  D.T.	  Finegood	  et	  al.,	  2001;	  A.	  Pick	  et	  
al.,	  1998;	  E.	  Shafrir	  et	  al.,	  1999;	  T.	  Tomita	  et	  al.,	  1992).	  	  
However,	   these	   rodent	   models	   do	   not	   fully	   mimic	   the	   pathological	   features	   of	   human	   T2DM.	   In	  
particular,	  amyloid	  deposition	  is	  not	  present	  because	  rodent	  IAPP	  is	  not	  amyloidogenic,	  and	  animals	  
require	  an	  extreme	  obese	  phenotype	  to	  eventually	  develop	  diabetes.	  Other	   rodent	  models	   include	  
the	  high	  calories-­‐fed	  sand	  rat	  (Psammomys	  obesus)	  and	  the	  Goto	  Katazaki	  rat	  (GK	  rat).	  The	  sand	  rat	  
develops	  insulin	  resistance	  and	  hyperglycemia	  within	  few	  days	  when	  fed	  high	  energy	  diet.	  Although	  
an	   extreme	   obese	   phenotype	   is	   not	   needed	   to	   provoke	   diabetes,	   this	   rat	   model	   also	   does	   not	  
develop	  amyloid	  deposition	  (E.	  Shafrir	  and	  A.	  Gutman,	  1993;	  M.Y.	  Donath	  et	  al.,	  1999).	  The	  GK	  rat	  is	  a	  
non	  obese	  rat	  having	  decreased	  β-­‐cell	  mass	  at	  birth	  due	  to	  defective	  β-­‐cell	  proliferation	  (B.	  Portha	  et	  
al.,	   2001;	   J.	  Movassat	  et	   al.,	   1997).	   It	   is	   characterized	  by	  a	   slight	   increase	   in	   fasted	  glucose	  due	   to	  
impaired	  insulin	  secretion	  and	  by	  the	  presence	  of	  insulin	  resistance	  in	  liver	  and	  skeletal	  muscles.	  As	  
in	  the	  other	  rodent	  models,	  however,	  there	  is	  no	  amyloid	  deposition	  in	  the	  islets	  (F.	  Picaret-­‐Blanchot	  
et	  al.,	  1996).	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The	   lack	   of	   amyloidogenesis	   in	   all	   these	   rodent	   models	   of	   T2DM	   is	   due	   to	   the	   absence	   of	  
amyloidogenic	   sequence	   in	   the	   rodent	   IAPP.	   To	   investigate	   the	   pathogenic	   effects	   of	   amyloid	  
formation	  and	  to	  test	  targeted	  treatment	  in	  vivo,	  transgenic	  mice	  and	  rats	  carrying	  human	  IAPP	  were	  
generated.	  The	  first	  mouse	  model	  was	  the	  hemizygous	  FVB/N-­‐Tg(Ins2-­‐IAPP)RHF/Soel/J	  mouse	  that	  is	  
transgenic	  for	  human	  IAPP;	  these	  mice	  developed	  diabetes	  only	  if	  treated	  with	  dexamethasone	  and	  
growth	  hormone	  for	  one	  month	  in	  order	  to	  induce	  marked	  insulin	  resistance	  (M.	  Couce	  et	  al.,	  1996;	  
E.J.	  De	  Koning	  et	  al.,	  1994,	  K.	  Yagui	  et	  al.,	  1995).	  These	  mice	  showed	  evidence	  of	  β-­‐cell	  degeneration	  
and	  small	  intra-­‐	  and	  extracellular	  amyloid	  deposition.	  	  
In	   1996,	   Janson	   et	   al.	   generated	   a	   new	   hIAPP	   transgenic	   mouse	   model,	   the	   homozygous	   FVB/N-­‐
Tg(Ins2-­‐IAPP)RHF/Soel/J	   mouse	   (J.	   Janson	   et	   al.,	   1996).	   In	   homozygous	   male	   mice,	   diabetes	  
developed	  spontaneously,	  at	  4	  -­‐	  8	  weeks	  of	  age	  due	  to	  rapid	  β-­‐cell	  death,	  impaired	  insulin	  secretion	  
and	  hyperglycemia.	  If	  untreated,	  male	  mice	  died	  around	  16	  weeks	  of	  age,	  as	  a	  consequence	  of	  severe	  
hyperglycemia.	   Interestingly,	   only	   small	   intracellular	   IAPP	   aggregates	   were	   present	   that	   could	   be	  
detected	   by	   electron	  microscopy.	   The	   homozygous	   females	   developed	   a	  much	  milder	   phenotype,	  
including	  mild	  hyperglycemia	  by	  16	  weeks	  of	  age	   (see	  Table	  2).	  Because	   their	  plasma	   insulin	   levels	  
were	  similar	  to	  those	  of	  wild	  type	  females,	  the	  authors	  suggested	  a	  defect	  in	  insulin	  secretion	  in	  the	  
homozygous	  male	  mice	  (J.	  Janson	  et	  al.,	  1996).	  The	  sexual	  dimorphism	  may	  rely	  on	  divergent	  effects	  
of	  estrogens	  versus	  androgens	  on	  hepatic	  estrogen	  sulfotransferase.	  Androgens	  may	  cause	  relative	  
insulin	   resistance	   in	  male	  mice	   (A.M.	   Gill	   et	   al.,	   1994)	   and	  may	   therefore	   contribute	   to	   the	   faster	  











MICE	  hIAPP/FBV/N	   Hemizygous	   Homozygous	  
Phenotype	  	  
Normal	  weight	  	   Normal	  weight	  (or	  slightly	  
decreased)	  
Sexual	  dimorphism	  	  
Diabetes	  development	  	  
Do	  not	  develop	  diabetes	  
spontaneously	  	  
Male:	  	  	  	  	  Onset:	  	  4-­‐8	  wk	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Death:	  	  16	  wk	  
Female:	  Onset:	  ≥30	  wk	  (in	  20%)	  	  
Plasma	  levels	  	  
	   Male:	  8-­‐16	  wks:	  	  	  	  	  	  ↑IAPP	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  ↓Insulin	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  ↑Glucose	  	  
Female	  14-­‐16	  wks:	  ↑	  IAPP	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  ↑Glucose	  
Islet	  pathology	  	  
β-­‐cell	  degeneration	   abnormal	  islet	  morphology	  	  
↓	  β-­‐cell	  mass,	  number	  
β-­‐cell	  degeneration	  
Pancreatic	  Amyloid	  	  
In	  insulin	  resistant	  mice:	  	  
perivascular	  extracellular	  
Congo	  Red	  +	  deposits	  visible	  
with	  light	  microscopy	  
Intra-­‐and	  extracellular	  amylin	  
deposits.	  
Fibrillar	  aggregates	  (5-­‐26	  wk)	  
visible	  with	  electron	  
microscopy	  	  
Table	   2:	   Summary	   of	   differences	   between	   homo-­‐	   and	   hemizygous	   FVB/N-­‐Tg(Ins2-­‐IAPP)RHF/Soel/J	  
mice,	  wk	  =	  week,	  ↑=	  increased,	  ↓=	  decreased	  (adapted	  from	  M.	  Couce	  et	  al.,	  1996;	  J.	  Janson	  et	  al.,	  
1996)	  
Other	  human	  IAPP	  transgenic	  mouse	  models	  were	  generated	  by	  cross-­‐breeding	  hemizygous	  FVB/N-­‐
Tg(Ins2-­‐IAPP)RHF/Soel/J	  mice	  with	  obese	  Avy/Agouti	   or	   ob/ob	  mice	   The	   resulting	  mice	   showed	  an	  
increased	   expression	   of	   the	   human-­‐IAPP,	   developed	   diabetes	   and	   islet	   amyloid	   deposition	   (A.E.	  
Butler	   et	   al.,	   2003;	   Hoppener	   et	   al.,	   1999;	   Soeller	   et	   al.,	   1998).	   Hemizygous	   FVB/N-­‐Tg(Ins2-­‐
IAPP)RHF/Soel/j	  mice	  were	   also	   cross	  with	   C57BL/6	   x	   DBA	  mice.	   If	   fed	   a	   high	   fat	   diet,	   these	  mice	  
developed	   diabetes	   and	   showed	   evidence	   of	   decreased	   β-­‐cell	   mass	   and	   presence	   of	   extracellular	  
amyloid	  deposits;	   the	  DBA	  background	  may	  have	   caused	  an	   increased	   susceptibility	   to	  dietary	   fat-­‐
related	  factors	  and	  an	  increased	  insulin	  and	  hence	  IAPP	  release	  (R.L.	  Hull	  et	  al.,	  2005;	  F.	  Wang	  et	  al.,	  
2001)	  
A	  human	  IAPP	  transgenic	  rat	  model	  has	  also	  been	  generated	  on	  a	  Sprague	  Dawley	  background,	  the	  
HIP	  rat	  (A.E.	  Butler	  et	  al.,	  2004).	  Homozygous	  rats	  develop	  diabetes	  rapidly	  within	  2	  months	  of	  age	  
without	  extracellular	  amyloid	  deposition,	  while	  hemizygous	  developed	  the	  disease	  at	  older	  age	  (6-­‐12	  
months	  of	  age)	  with	  the	  presence	  of	  extensive	  amyloid	  deposits	  (A.E.	  Butler	  et	  al.,	  2004).	  	  
In	   summary,	   these	   transgenic	   rodent	   models	   may	   be	   more	   useful	   for	   the	   study	   of	   T2DM	   than	  
traditionally	  used	  models.	  Differences	  in	  the	  genetic	  background	  as	  well	  as	  the	  rate	  of	  expression	  of	  
the	  transgene	  may	  be	  responsible	  for	  the	  variable	  phenotypes,	  including	  differences	  in	  the	  presence	  
of	  visible	  amyloid	  deposits.	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Aim	  of	  the	  study	  
In	   the	   current	   study,	   a	   passive	   immunotherapy	   targeting	   toxic	   aggregates	   of	   IAPP	   was	   tested	   in	  
FVB/N-­‐Tg(Ins2-­‐IAPP)RHF/Soel/J	   homozygous	   mice.	   Human	   anti-­‐hIAPP	   antibodies	   showing	   high	   in	  
vitro	   binding	   selectivity	   and	   affinity	   against	   hIAPP	   aggregates	   were	   first	   isolated	   from	   blood	   of	  
healthy	   human	   donors,	   cloned,	   purified	   and	   characterized	   in	   order	   to	   be	   administered	  
intraperitoneally	  in	  our	  mouse	  model.	  
Our	   aim	   was	   to	   study	   the	   therapeutic	   efficacy	   of	   the	   anti-­‐hIAPP	   antibodies	   to	   slow	   diabetes	  
progression	   in	   this	   transgenic	   mouse	   model	   of	   T2D	   expressing	   human	   IAPP.	   The	   efficacy	   of	   the	  
immunotherapy	   was	   assessed	   by	   determining	   plasma	   levels	   of	   insulin	   and	   glucose	   during	   glucose	  
tolerance	  tests,	  together	  with	  hIAPP	  amyloid	  load	  in	  the	  pancreas.	  
	  
Materials	  and	  methods	  
1. Preparation	  of	  transgenic	  construct	  
The	  RIPHAT	  transgene	  construct	  was	  produced	  with	  PCR-­‐generated	  cDNA	  of	  the	  human	  IAPP	  coding	  
sequence	   under	   the	   regulatory	   control	   of	   the	   rat	   insulin	   II	   ins2	   promoter/5’UTR	   (untranslated	  	  
leading	   region)	   and	   the	   human	   albumin	   intron	   I.	   It	   was	   followed	   by	   polyadenylation	   signal	   /RNA	  
termination	   region	   from	   the	   glyceraldehydes-­‐3-­‐phosphate	   gene	   and	   3’UTR,	   as	   shown	   in	   Fig.	   4	   (M.	  
Couce	  et	  al.,	  1996;	  J.	  Janson	  et	  al.,	  1996).	  
	  
Fig	  4:	  Restriction	  map	  of	  the	  RIPHAT	  transgene	  (2395	  bp):	  PCR-­‐generated	  cDNA	  human	  IAPP	  coding	  
sequence	   (first	   striped	   box);	   RIP	   II	   promoter,	   the	   rat	   ins2	   promoter	   and	   5’UTR	   (white	   box).	   Alb.	  
intron,	   human	   albumin	   intron	   I	   (light-­‐shaded);	   poly	   A,	   polyadenylation	   signal	   /RNA	   termination	  
region	  from	  the	  glyceraldehydes-­‐3-­‐phosphate	  gene	  and	  3’UTR	  (second	  striped	  box).	  Bam	  HI,	  Eco	  RI	  
and	  Hind	   III	   are	   type	   II	   restriction	  endonuclease	   isolated	   from	  Bacillus	  amyloli,	   Escherichia	  coli	   and	  
Hemophilus	  influenza,	  respectively	  (adapted	  from	  W.C.	  Soeller	  et	  al.,	  2001)	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2. Generation	  of	  transgenic	  mice	  
FVB/N-­‐Tg(Ins2-­‐IAPP)RHF/Soel/J	   (JAX	   stock	   008232)	   transgenic	   mice	   were	   generated	   and	  
characterized	   at	   Jackson	   Laboratory	   (Bar	   Harbour,	   USA),	   as	   previously	   described	   (M.	   Couce	   et	   al.,	  
1996;	  J.	  Janson	  et	  al.,	  1996;	  W.C.	  Soeller	  et	  al.,	  2001).	  The	  entire	  RIPHAT	  transgene	  was	  cloned	  into	  
plasmid	  pBluescript	   to	  generate	  pRIPHAT1.	  The	  pRIPHAT1	  was	  digested	  with	  endonuclease	  BamHI,	  
followed	  by	  agarose	  electrophoresis,	  electroelution	  of	  the	  DNA	  from	  the	  gel	  slice,	  and	  purification	  on	  
a	   Schleicher	   and	   Schuell	   Elutip	   column,	   in	   order	   to	   obtain	   a	   2.4kb	   linear	  DNA	   fragment,	   ready	   for	  
microinjection.	  The	  DNA	   fragment	  was	   then	  microinjected	   in	  pronuclei	  of	  FVB/N	   fertilized	  oocytes,	  
which	  were	  implanted	  in	  pseudogravid	  females	  to	  produce	  fertile	  offspring	  expressing	  the	  hIAPP.	  The	  
FVB/N	  inbred	  mouse	  strain	  was	  chosen	  as	  background	  to	  produce	  the	  transgenic	  animals	  because	  it	  
is	   known	   that	   this	   strain	   is	   preferable	   for	   transgenic	   experiments	   and	   analyses.	   The	   phenotype	   of	  
these	  mice	  shows	  fertilized	  ovocytes	  with	  large	  pronuclei,	  which	  facilitates	  DNA	  microinjection	  (see	  
Fig.	   5;	   Taketo	   et	   al,	   1991).	   Founder	   animals	   were	   identified	   by	   PCR	   amplification	   of	   transgene	  
sequences	   from	   tail	   DNA.	   The	   RHF	   transgenic	   line,	   the	   founder	   line,	   was	   selected	   based	   on	   their	  
higher	  level	  of	  RNA	  expression	  of	  hIAPP	  in	  the	  pancreas.	  High	  resolution	  mapping	  of	  the	  transgene	  in	  
prometaphase	  spreads	  of	  endoreduplicated	  cells	  indicates	  the	  transgene	  insertion	  at	  a	  single	  location	  
on	  chromosome	  15	  (15C).	  
	  
	  
Fig	  5:	  Scheme	  representing	  the	  production	  of	  transgenic	  mice.	  	  
(Adapted	  from	  M.	  Couche	  et	  al.	  1996;	  and	  from	  the	  web	  site	  of	  the	  Department	  of	  Nutrition	  &	  Food	  
Science	  at	  Wayne	  State	  University,	  clasweb.clas.wayne.edu/NFS)	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   2a.	  	   Breeding	  plan	  
For	   the	   current	   study,	   breeding	   pairs	   of	   transgenic	   FVB/N-­‐Tg(Ins2-­‐IAPP)RHFSoel/J	   (JAX	   stock	   No.	  
008232)	   mice	   were	   purchased	   from	   Jackson	   Laboratory	   (Bar	   Harbor,	   USA).	   Two	   matings	   were	  
performed	   by	   crossing	   hemizygous	   males	   (FVB	   (hIAPP)	   tg/-­‐;	   n=8)	   with	   hemizygous	   females	   (FVB	  
(hIAPP)	  tg/-­‐;	  n=15),	  following	  a	  trio	  mating	  scheme	  (one	  male	  with	  two	  to	  three	  females).	  Transgenic	  
offspring	  was	  identified	  by	  PCR	  amplification	  of	  the	  RIPHAT	  from	  ear	  DNA	  as	  described	  by	  Couce	  (M.	  
Couce	   et	   al.,	   1996).	   Hemizygous	   mice	   were	   distinguished	   from	   homozygous	   by	   quantitative	   PCR.	  
After	   the	   first	  mating,	  23	   transgenic	  males	   (hemizygous	  n=17;	  homozygous	  n=6)	  and	  22	   transgenic	  
females	  (hemizygous	  n=16;	  homozygous	  n=6)	  were	  obtained.	  Homozygous	  mice	  were	  also	  generated	  
using	   a	   homozygous	   female	   x	   homozygous	  male	   breeding	   scheme.	   After	   two	  matings	   using	   three	  
homozygous	   breeding	   pairs,	   19	   homozygous	   females	   and	   25	   homozygous	   males	   were	   generated.	  
Mice	   received	   water	   and	   conventional	   chow	   diet	   ad	   libitum	   (Kliba	   Nafag	   3436,	   Provimi	   Kliba	   AG,	  
Kaiseraugst,	  CH)	  and	  were	  kept	  on	  a	  12	  hours	  light/dark	  cycle.	  F1	  and	  F2	  male	  offspring	  were	  used	  in	  
the	   experiment.	   All	   animal	   experiments	   have	   been	   approved	   by	   the	   Cantonal	   Veterinary	  Office	   of	  
Zurich,	  Switzerland	  (licence	  #121/2012).	  
	  
3.	  	   Genotyping	  
3a.	  	   DNA	  extraction	  
At	  two	  weeks	  of	  age,	  ear	  biopsies	  were	  taken	  from	  the	  mice	  to	  perform	  the	  genotyping.	  
Tissues	  were	  lysed	  using	  20mg/ml	  Proteinase	  K	  (Promega,	  Madison,	  USA)	  and	  2XPK	  buffer	  (200mM	  
Tris-­‐HCl	  pH	  7.5,	  2.5mM	  EDTA,	  300mM	  NaCl,	  2%	  SDS).	  The	  DNA	  was	  purified	  by	  centrifugation	  with	  
phenol-­‐chloroform	  (Carl	  Roth,	  Arlesheim,	  CH),	  precipitated	  with	  ethanol	  and	  sodium	  acetate	  (pH	  5.5)	  
washed	  again	  with	  ethanol	  and	  resuspended	  in	  TE	  buffer	  (Tris-­‐EDTA	  buffer,	  pH	  8.0,	  Promega).	  	  
3b.	  	   Standard	  PCR	  
After	  DNA	  extraction,	  the	  presence	  of	  the	  hIAPP	  transgene	  in	  the	  offspring	  was	  determined	  by	  PCR.	  
This	   technique	   differentiates	   transgenic	   carriers	   from	   wild	   type	   mice	   but	   does	   not	   allow	   to	  
distinguish	   between	   homo-­‐	   and	   hemizygous	   Amplification	   was	   performed	   by	   Go	   Taq	   DNA	  







Products	   Quantity	  	  	  
10x	  AB	  PCR	  Buffer	  (Applied	  Biosystems,	  Zug,	  CH)	   1.20	  µl	  
25	  mM	  MgCl2	  (Applied	  Biosystems)	   0.96	  µl	  
2.5	  mM	  dNTP	  (Promega)	   0.96	  µl	  
20	  µM	  Transgene	  Forward	   0.60	  µl	  
20	  µM	  Transgene	  Reverse	   0.60	  µl	  
20	  µM	  Internal	  Positive	  Control	  Forward	   0.25	  µl	  
20	  µM	  Internal	  Positive	  Control	  Reverse	   0.25	  µl	  
5	  mM	  DNA	  Loading	  Dye	  (Promega)	   1.66	  µl	  
5	  U/µl	  Taq	  DNA	  polymerase	  (Promega)	   0.06	  µl	  
ddH2O	  (Qiagen,	  Hilden,	  DE)	   3.46	  µl	  
DNA	  sample	   2.00	  µl	  
Table	  3:	  Quantity	  of	  reagents	  used	  for	  the	  amplification	  of	  one	  sample	  in	  the	  PCR	  reaction.	  	  
Primers	   for	   the	   genotyping	   of	   the	   hIAPP	   gene	   are	   reported	   in	   Table	   4.	   The	   reaction	  mixture	   also	  
included	  primers	   for	  an	   internal	  positive	  control,	  which	  consists	  of	  primers	   that	  amplify	  a	  genomic	  
DNA	   region,	   the	  mouse	   interleukin	   2	   (IL2)	   gene	   that	   is	   unrelated	   to	   the	   transgene	   (see	   Table	   4).	  
Successful	   amplification	   of	   the	   internal	   control	   indicates	   that	   the	   DNA	   is	   suitable	   for	   the	   PCR.	   All	  
primers	  were	  purchased	  from	  Microsynth	  (Balgach,	  CH).	  
Sequence	  (from	  5’	  to	  3’)	   Primers	  
CTA	  GGC	  CAC	  AGA	  ATT	  GAA	  AGA	  TCT	   Internal	  positive	  control	  forward	  (Il-­‐2)	  
GTA	  GGT	  GGA	  AAT	  TCT	  AGC	  ATC	  ATC	  C	   Internal	  positive	  control	  	  reverse	  (Il-­‐2)	  
GTC	  ATG	  TGC	  ACC	  TAA	  AGG	  GGC	  AAG	  TAA	  TTC	  A	   IAPP	  transgene	  forward	  
CGA	  GTG	  GGC	  TAT	  GGG	  TTT	  GT	   IAPP	  transgene	  reverse	  
Table	  4:	  Primers	  and	  respective	  sequence	  used	  for	  the	  PCR	  reaction.	  
The	   Thermal	   cycle	   reaction	  was	   set	   as	   shown	   in	   Table	   5.	   All	   PCR	   reactions	  were	   carried	   out	   with	  
Personal	  thermocycler	  instrument	  (Biometra	  GmbH,	  Goettingen,	  Germany).	  
Cycling	  Step	  #	   Temperature	  °C	   Time	   Notes	  
1	   94	   3	  min	   Melting	  
2	   94	   30	  sec	   Denaturation	  
3	   63	   1	  min	   Annealing	  	  
4	   72	   1	  min	   Extension	  
Repeat	   2-­‐4	   for	   35	  
cycles	  
5	   72	   2	  min	   	  
Table	  5:	  Settings	  for	  the	  PCR	  program.	  	  
	   3c.	  	  Agarose	  gel	  electrophoresis	  
2g	   of	   agarose	   (MP	   Biomedicals,	   Santa	   Ana,	   USA)	  were	   dissolved	   in	   100ml	   Tris-­‐acetate-­‐EDTA	   (TAE)	  
buffer	  and	  heated	  in	  the	  microwave	  for	  approximately	  1.5	  minutes.	  After	  cooling	  the	  solution	  for	  5	  
24	  
minutes,	  5µl	  of	  Roti-­‐safe	  dye	  (Carl	  Roth,	  Karlsruhe,	  Germany)	  were	  added	  and	  mixed	  to	  the	  solution.	  
While	  still	  fluid,	  the	  gel	  was	  poured	  into	  a	  clean	  gel	  mold	  and	  a	  fitting	  comb	  was	  inserted.	  	  
After	  solidification,	  the	  gel	  was	  transferred	   into	  the	  electrophoresis	  chamber,	  which	  was	  filled	  with	  
TAE	   buffer	   until	   the	   entire	   gel	   was	   covered.	   After	   removing	   the	   comb,	   the	   PCR	   products	   were	  
carefully	  loaded	  in	  the	  gel	  wells	  (12µl	  for	  each	  sample).	  A	  100bp	  DNA	  ladder	  was	  used	  (Gene	  ruler	  0.5	  
µg/µl,	  Fermentas,	  Wohlen,	  CH).	  Electrophoresis	  was	  run	  at	  140	  V	  for	  40	  min.	  DNA	  bands	  migration	  
was	  observed	  under	  UV	  illumination	  with	  Biorad	  UV	  Light	  and	  Gel	  Documentation	  Hood	  (Life	  Science	  
Group	  Switzerland,	  Reinach,	  CH).	  	  
	  
	  
Fig	  6:	  Example	  of	  agarose	  gel.	  Transgene	  and	  Internal	  Positive	  Control	  have	  a	  length	  of	  approximately	  
954	   bp	   and	   324	   bp,	   respectively.	   A	   100bp	   DNA	   ladder	   scale	   was	   used.	  	  
(Adapted	  from	  the	  Jackson	  Laboratory	  website,	  http://jaxmice.jax.org/strain/008232.html)	  
	  
	   3d.	  	   Quantitative	  PCR	  (qPCR)	  
Quantitative	   PCRs	   were	   performed	   to	   differentiate	   homo-­‐	   from	   hemizygous	   mice.	   The	   transgene	  
expression	   was	   calculated	   for	   each	   animal	   that	   was	   recognized	   as	   transgenic.	   DNA	   samples	   were	  









Internal	  control	  (324bp)	  
tg	  	  	  tg	  	  tg	  	  tg	  	  	  	  	  wt	  	  wt	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Products	   Quantity	  
2x	  KAPA	  Probe	  fast	  qPCR	  
	  
10	  µl	  
40	  uM	  12855	  (transgene	  forward)	   0.28	  µl	  
40	  uM	  12856	  (transgene	  reverse)	   0.28	  µl	  
40	  uM	  oIMR1544	  (reference	  gene	  forward)	   0.28	  µl	  
40	  uM	  oIMR3580	  (reference	  gene	  reverse)	   0.28	  µl	  
5	  uM	  12857	  (transgene	  probe)	   0.81	  µl	  
5	  uM	  TmoIMR0105	  (reference	  gene	  probe)	  
	  
0.81	  µl	  
DNA	  (1:10)	   5	  µl	  
Table	  6:	  Quantity	  of	  reagents	  used	  for	  the	  amplification	  of	  one	  sample	  in	  the	  qPCR	  reaction.	  	  
Primers	  and	  probes	  were	  purchased	  from	  Microsynth	  (see	  Table	  7).	  The	  internal	  control	  primer	  and	  
probe	   set	   amplify	   a	   fragment	   of	   the	   Apoprotein	   B	   mouse	   gene	   (ApoB).	   The	   reaction	   requires	   a	  
hybridization	   probe	   labeled	   with	   two	   fluorescent	   dyes.	   One	   dye	   is	   a	   reporter	   dye	   (FAM)	   and	   the	  
other	   is	  a	  quenching	  dye	  (black	  hole	  quencher,	  BHQ).	  When	  the	  probe	   is	   intact,	   fluorescent	  energy	  
transfer	   occurs	   and	   the	   reporter	   dye	   emission	   is	   absorbed	   by	   the	   quenching	   dye.	   During	   the	  
extension	   phase	   of	   the	   PCR	   cycle,	   the	   fluorescent	   hybridization	   probe	   is	   cleaved	   by	   the	   5’-­‐3’	  
nucleolytic	  activity	  of	  the	  DNA	  polymerase.	  When	  the	  probe	  is	  cleaved,	  the	  reporter	  dye	  emission	  is	  
no	   longer	   transferred	   efficiently	   to	   the	   quenching	   dye,	   resulting	   in	   an	   increase	   of	   the	   reporter	  
emission	   spectra.	   Fluorescence	   is	  measured	  with	   time	  and	   corresponds	   to	   the	  amplification	  of	   the	  
corresponding	  gene	  sequences.	  This	  is	  converted	  in	  cycle	  threshold	  (CT)	  values.	  	  
Sequence	  (from	  5’	  to	  3’)	   Primers	  and	  probes	  	  
CAG	  CGC	  CTG	  GCA	  AAT	  TTT	  	   IAPP	  transgene	  forward	  
GCA	  TTC	  CTC	  TTG	  CCA	  TAT	  GTA	  TTG-­‐3’	   IAPP	  transgene	  reverse	  
FAM-­‐CCA	  CGT	  TGG	  TAG	  ATG	  AGA	  GAA	  TGG	  CAC-­‐BHQ1	   IAPP	  Transgene	  probe	  
CAC	  GTC	  GGC	  TCC	  AGC	  ATT’	   ApoB	   gene	   forward	   (internal	   positive	  
control)	  
TCA	  CCA	  GTC	  ATT	  TCT	  GCC	  TTT	  G	   ApoB	   Gene	   reverse	   (internal	   positive	  
control)	  
Cy5-­‐	  CCA	  ATG	  GTC	  GGG	  CAC	  TGC	  TCA	  A-­‐BHQ2	   ApoB	   gene	   probe	   (internal	   positive	  
control)	  
Table	  7:	  Primers	  and	  probes	  used	  for	  the	  qPCR.	  
	  
The	   comparative	   cycle	   threshold	   (CT)	   method,	   also	   known	   as	   the	   2
-­‐ΔΔCt
	   method,	   was	   used	   for	  
quantification.	  The	  threshold	  on	  amplification	  curves	   is	  set	  based	  on	  the	  variability	  of	  the	  base-­‐line	  
data.	  Ct	  values	  were	  exported	  and	  used	  for	  calculating	  the	  genotypes.	  For	  the	  analysis,	  ΔΔCt	  of	  the	  
reference	  gene	  and	   the	   transgene	  were	  used.	  Mean	  Ct	   values	  and	   standard	  deviations	  of	   the	   four	  
measurements	  for	  the	  reference	  gene	  and	  the	  transgene	  were	  calculated	  as	  follows:	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A	  heterozygous	  control	  sample	  was	  used	  as	  reference	  sample	  for	  each	  calculating	  ΔΔCt.	  	  
An	   unknown	   sample	  with	   a	   zygosity	   factor	   approaching	   1	   or	   2	   was	   analyzed	   as	   hemizygote	   or	   as	  
homozygote,	  respectively.	  
All	  qPCR	  reactions	  were	  carried	  out	  in	  the	  7500	  Real	  Time	  PCR	  System	  thermocycler	  instrument	  from	  
Applied	  Biosystems	  (Foster,	  USA).	  The	  thermal	  cycle	  reaction	  for	  the	  qPCR	  was	  set	  as	  shown	  in	  Table	  
8.	  
Cycling	  step	  #	   Temperature	  °C	   Time	  
1	   95	   10	  minutes	  
2	   95	   15	  seconds	   Repeated	   2-­‐3	   for	   40	  
cycles	  3	   60	   1	  minute	  
Table	  8:	  Settings	  for	  the	  qPCR	  program.	  	  
4.	  	  Study	  design	  
4.a.	   Injection	  protocol	  	  
A	  total	  of	  40	  male	  mice	  (homo-­‐	  and	  hemizygous	  mice)	  were	  included	  in	  the	  experiment	  (see	  Table	  9).	  
The	  experiments	  were	  run	  in	  three	  series	  under	  identical	  experimental	  conditions.	  Hemizygous	  mice	  
were	  used	  as	  control	  group	  (hemi-­‐PBS)	  to	  establish	  reference	  baseline	  values.	  Hemi-­‐PBS	  (n=10)	  were	  
injected	  weekly	  intraperitoneally	  (i.p.)	  with	  phosphate	  buffered	  saline	  (PBS,	  pH	  7.4,	  10ml/kg,	  Gibco,	  
Auckland,	  NZ).	  Homozygous	  mice	  were	  randomly	  assigned	  to	  homozygous-­‐PBS	  (homo-­‐PBS,	  n=14)	  or	  
experimental	  homozygous-­‐antibody	   (homo-­‐AB,	  n=16)	  groups	  and	   then	  administered	  PBS	   (10ml/kg)	  
or	   human	   anti-­‐hIAPP	   antibodies	   (10mg/kg	   murinized	   NI-­‐203.A),	   respectively.	   I.p.	   injections	   were	  
started	  in	  all	  mice	  at	  four	  weeks	  of	  age,	  and	  were	  repeated	  weekly	  until	  the	  end	  of	  the	  experiment	  at	  
three	   months	   of	   age.	   Body	   weight	   was	   measured	   weekly.	   Intraperitoneal	   glucose	   tolerance	   tests	  
(ipGTTs)	  were	  performed	  at	  one,	  two	  and	  three	  months	  of	  age.	  The	  ipGTT	  at	  one	  month	  of	  age	  was	  
performed	  just	  before	  any	  treatment	  was	  started	  and	  served	  as	  baseline.	  Fasting	  glucose	  and	  insulin	  
levels	  were	  measured	  before	  every	  ipGTT.	  	  






Set	  1	   0	   5	   6	  
Set	  2	   7	   6	   7	  
Set	  3	   3	   3	   3	  
Total	   10	   14	   16	  
Table	  9:	  Total	  number	  of	  mice	  used	  in	  the	  experiment.	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4b.	  	   Human	  anti-­‐IAPP	  antibodies	  
Human	   anti-­‐IAPP	   antibodies	   were	   produced	   by	   Neurimmune	   Holding	   AG	   (Schlieren,	   CH).	   Reactive	  
memory	  B-­‐cells	  were	  isolated	  from	  the	  blood	  of	  healthy	  human	  patients.	  Antibodies	   in	  conditioned	  
media	  of	  human	  memory	  B	  cell	  cultures	  were	  screened	   in	  parallel	   for	  binding	  to	  aggregated	  hIAPP	  
protein	  and	  absence	  of	  binding	  to	  bovine	  serum	  albumin	  (BSA)	  using	  a	  direct	  ELISA	  approach.	  Only	  B-­‐
cell	   cultures	   positive	   for	   aggregated	   hIAPP	   protein	   but	   not	   for	   BSA	   were	   subjected	   to	   antibody	  
cloning.	   Selected	   relevant	   antibodies	   were	   recombinantly	   produced	   and	   characterized	   for	   their	  
binding	   specificities	   towards	   aggregated	   or	   non-­‐aggregated	   hIAPP	   protein.	   Antibody	   selection	   and	  
characterization	  was	  performed	  by	  direct	  ELISA	  on	  96-­‐well	  plates	  (Costar,	  Corning,	  USA)	  coated	  with	  
human	  IAPP	  solution	  or	  BSA	  (Bovine	  Serum	  Albumin,	  Sigma-­‐Aldrich,	  Buchs,	  Switzerland)	  diluted	  to	  a	  
concentration	   of	   10	   µg/ml	   in	   carbonate	   buffer	   (15	   mM	   Na2CO3,	   35	   mM	   NaHCO3,	   pH	   9.42).	   After	  
overnight	   incubation	   at	   room	   temperature,	   non-­‐specific	   binding	   sites	   were	   blocked	   for	   1	   hour	   at	  
room	   temperature	   with	   PBS/0.1%	   Tween-­‐20	   (polysorbate	   surfactant)	   containing	   2%	   BSA	   (Sigma-­‐
Aldrich,	  Buchs,	  Switzerland).	  B-­‐cell	  conditioned	  medium	  or	  recombinantly	  produced	  antibodies	  were	  
transferred	   to	   ELISA	   plates	   and	   incubated	   for	   one	   hour	   at	   room	   temperature.	   ELISA	   plates	   were	  
washed	   in	   PBS-­‐Tween	   20	   and	   binding	   was	   determined	   using	   horseradish	   peroxidase	   (HRP)-­‐
conjugated	  anti-­‐human	   IgG	  polyclonal	  antibodies	   (Jackson	   ImmunoResearch,	  Newmarket,	  UK).	  HRP	  
activity	  was	  assessed	  with	  standard	  colorimetric	  detection	  using	  a	  plate	  reader	   (Sunrise	  microplate	  
absorbance	  reader,	  Tecan	  Group	  Ltd,	  Männedorf,	  Switzerland).	  	  
In	   case	   B-­‐cell	   conditioned	  medium	   showed	   antibodies	   with	   selective	   binding	   to	   aggregated	   hIAPP	  
protein,	  mRNA	  of	  B-­‐cells	  was	  prepared	  and	  immunoglobulin	  heavy	  and	  light	  chains	  were	  cloned	  with	  
a	  nested	  PCR	  approach.	  The	  PCR	  approach	  consists	  in	  a	  modified	  polymerase	  chain	  reaction	  intended	  
to	   reduce	   non-­‐specific	   binding	   in	   products	   due	   to	   the	   amplification	   of	   unexpected	   primer	   binding	  
sites.	  
Antibodies	   were	   identified	   by	   rescreening	   on	   ELISA	   upon	   recombinant	   expression	   of	   complete	  
antibodies	  in	  CHO	  (Chinese	  Hamster	  Ovary)	  cells	  and	  using	  expression	  vectors,	  where	  variable	  heavy	  
and	  light	  chain	  sequences	  “in	  the	  correct	  reading	  frame”	  were	  inserted.	  An	  Ig-­‐heavy-­‐chain	  expression	  
vector	  and	  a	  kappa	  or	  lambda	  Ig-­‐light-­‐chain	  expression	  vector	  were	  used.	  The	  monoclonal	  antibodies	  
were	   purified	   with	   standard	   protein	   A	   column	   purification	   and	   tested	   again	   for	   their	   binding	  
properties	  by	  ELISA.	  
Figure	   7	   shows	   direct	   ELISA	   results	   of	   the	   recombinant	   human	   NI-­‐203.26C11	   antibody.	   Figure	   8	  
shows	   an	   electron	  microscopy	   picture	   of	   the	   aggregated	   hIAPP	   solution	   used	   for	   the	   direct	   ELISA	  
assay	  andFigure	  9	  shows	  fibrillar	  and	  non	  fibrillar	  IAPP	  solutions.	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Fig.	   7:	   Results	   of	   direct	   ELISA	   assay	   showing	   binding	   selectivity	   of	   the	   human	   NI-­‐203.26C11	  
recombinant	  antibody	  	  against	  hIAPP	  aggregates	  (IAPP),	  with	  no	  binding	  to	  BSA.	  Data	  are	  expressed	  
as	  optical	  density	  values	  measured	  at	  450	  nm	  (Data	  from	  Neurimmune).	  
	  
Fig	   8:	   Electron	  microscopy	   picture	   of	   the	   aggregated	   hIAPP	   solution	   (2	  mg/ml)	   used	   for	   the	   direct	  
ELISA	  assay.	   Full-­‐length	  human	   IAPP	  peptide	   (1-­‐KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY-­‐37;	  
C-­‐term	  modification:	  amide)	  was	  purchased	  from	  Anaspec	  (Fremont,	  CA,	  USA).	  The	  IAPP	  solution	  was	  
prepared	  by	  dissolving	  native	  human	  IAPP	  in	  DMSO	  for	  24	  hours	  at	  room	  temperature	  with	  shaking	  
(40	  rpm).	  Scale	  bar	  represents	  1	  µm	  (Data	  from	  Neurimmune).	  
	  
After	   standard	   colorimetric	  detection	  on	  a	  plate	   reader,	   the	  EC50	   values	  were	  estimated	  by	  a	  non-­‐
linear	  regression	  using	  GraphPad	  Prism	  (San	  Diego,	  USA)	  software,	  as	  shown	  in	  Fig	  10.	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Fig.	  9:	  Electron	  microscopy	   images	  of	  aggregated	  human	   IAPP	  (IAPP,	  2	  mg/ml)	  and	  non	  aggregated	  
IAPP	  (2	  mg/ml)	  solutions	  used	  for	  ELISA	  plate	  coating.	  While	  the	  IAPP	  solution	  contains	  clearly	  visible	  
fibrils,	  IAPP	  fibrils	  are	  absent	  in	  the	  non	  aggregated	  IAPP	  solution.	  The	  non	  aggregated	  IAPP	  solution	  
shows	   small	   particles	   most	   likely	   corresponding	   to	   small-­‐size	   IAPP	   oligomer	   species.	   Scale	   bar	  
represents	  1	  µm	  (Data	  from	  Neurimmune).	  	  	  
	   	  
Fig	  10:	  Plates	  were	   incubated	  with	  the	   indicated	  concentrations	  of	  recombinant	  human-­‐derived	  NI-­‐
203.26C11	   antibody.	   NI-­‐203.26C11	   binds	   with	   high	   affinity	   to	   IAPP	   aggregates	   (IAPP	   solution,	   10	  
µg/ml)	  and	  with	  absence	  of	  binding	  to	  non-­‐aggregated	  IAPP	  (10	  µg/ml).	  Measurements	  were	  made	  in	  
duplicate	  and	  background	  signal	  on	  BSA	  was	  subtracted.	  Data	  are	  expressed	  as	  mean	  optical	  density	  
values	  at	  450	  nm	  (Data	  from	  Neurimmune).	  
	  
These	   findings	   suggest	   that	   NI-­‐203.26C11	   antibody	   binds	   a	   conformational	   epitope	   exposed	   on	  
aggregated	  IAPP	  species,	  but	  not	  to	  linear	  epitopes	  present	  in	  monomeric	  human	  IAPP	  molecules.	  	  
Finally,	   to	   avoid	   a	  mouse	   anti-­‐human	   antibody	   response,	   chimeric	   antibodies	   consisting	   of	   human	  
variable	   domains	   and	   murine	   constant	   regions	   were	   generated	   by	   protein	   engineering.	   Chimeric	  
IAPP Non aggregated IAPP 
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antibodies	  were	  recombinantly	  produced	  in	  CHO	  cells	  for	  further	   in	  vitro	  characterization	  and	  for	   in	  
vivo	   validation	   studies	   in	   transgenic	   mice.	   Endotoxin-­‐free	   antibodies	   for	   in	   vivo	   validation	   were	  
additionally	  purified	  by	  affinity	  chromatography.	  	  
4c.	  	   Intraperitoneal	  Glucose	  Tolerance	  Test	  (ipGTT)	  
The	  ipGTT	  protocol	  has	  been	  previously	  described	  by	  Ehses	  et	  al.	  (2010).	  After	  12	  hours	  fasting	  during	  
the	  dark	  phase,	  mice	  were	  put	  in	  a	  restrainer	  for	  blood	  sampling.	  The	  most	  distal	  part	  of	  the	  tail	  was	  
cut	  with	  a	  scalpel	  blade	  and	  blood	  was	  collected.	  Basal	  glycaemia	  and	   insulinemia	  were	  measured.	  
Animals	  were	  weighted	  and	  received	  an	  i.p.	  injection	  of	  20%	  glucose	  (2g/kg,	  10ml/kg).	  Blood	  glucose	  
and	  insulin	  levels	  were	  measured	  15,	  30,	  60,	  120	  and	  240	  min	  after	  glucose	  injection.	  Glycemia	  was	  
assessed	  using	  glucose	   strips	  and	  a	  glucometer	   (Breeze	  2,	  Bayer,	  Mijdrecht,	   The	  Netherlands).	   The	  
mean	  of	  two	  measurements	  was	  taken	  at	  every	  time	  point.	   If	  the	  measures	  differed	  by	  >	  2mmol,	  a	  
third	  measurement	  was	  taken.	  When	  glucose	  levels	  were	  above	  the	  measurement	  threshold	  of	  the	  
glucometer	   (33.3	   mmol/l),	   3µl	   of	   blood	   were	   diluted	   1:1	   with	   3µl	   NaCl	   (v/v).	   For	   insulin	  
measurements,	   25	   µl	   of	   blood	  were	   collected	   using	   a	   heparinized	   capillary.	   Blood	  was	   transferred	  
into	  a	  500	  µl	  Eppendorf	  tube	  containing	  EDTA	  (1/10;	  50mM	  EDTA	  in	  0.9%	  NaCl)	  on	  ice.	  Tubes	  were	  
centrifuged	  for	  5	  minutes	  at	  10’000	  rpm.	  Plasma	  (10	  µl)	  was	  transferred	  to	  a	  96	  well	  plate	  and	  stored	  
at	  -­‐20°C,	  for	  later	  analysis.	  	  
5.	  	   	   Insulin	  
Insulin	  plasma	  level	  was	  assessed	  with	  a	  mouse	  Insulin	  ELISA	  Kit	  from	  Mercodia	  (Uppsala,	  Sweden),	  
following	  the	  manufacturer’s	   instructions.	  The	  optical	  density	  was	  read	  at	  450	  nm	  with	  a	  Multiskan	  
ELISA	   reader	   device	   (Thermo	   Labsystems,	   Milford,	   USA)	   and	   the	   different	   concentrations	   were	  
calculated	  using	  cubic	  spline	  regression	  with	  the	  Ascent	  Software	  v.2.6	  (Thermo	  scientific,	  Waltham,	  
USA).	  In	  order	  to	  have	  reference	  values	  of	  untreated	  wild	  type	  mice,	  insulin	  levels	  of	  three	  12	  weeks	  
old	  C57Bl/6	  male	  mice	  were	  measured	  during	  an	  ipGTT.	  
6.	  	   Pancreas	  sampling	  and	  histology	  
After	  undergoing	  the	  third	  ipGTT	  at	  3	  months	  of	  age,	  mice	  were	  anesthetized	  with	  an	  i.p.	  injection	  of	  
pentobarbital	   (40	   mg/kg)	   and	   sacrificed	   by	   removing	   the	   blood	   from	   the	   caudal	   cave	   vein.	   The	  
pancreas	  was	   collected	   and	   fixed	  with	   4%	   paraformaldehyde	   (PFA)	   solution	   for	   24	   hours	   at	   room	  
temperature.	   The	   tissues	   were	   embedded	   in	   paraffin	   blocks,	   cut	   with	   a	   microtome	   (Leica,	  
Biosystems,	  Wetzlar,	  Germany)	  and	  mounted	  onto	  glass	  slides.	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6a.	   	  Thioflavin-­‐S	  staining	  
Thio-­‐S	   staining	   was	   performed	   in	   order	   to	   detect	   the	   presence	   of	   amyloid	   fibrils.	   Thio-­‐S	   binds	   to	  
amyloid-­‐fibrils	   but	   not	   to	   IAPP	   monomers.	   Thio-­‐S	   is	   a	   benzothiazole	   dye	   that	   exhibits	   enhanced	  
fluorescence	  upon	  binding	  to	  amyloid	  fibrils.	  The	  slides	  were	  heated	  at	  65°C	  for	  one	  hour.	  They	  were	  
incubated	   in	   the	   following	   series	   of	   solutions	   for	   deparaffinization	   and	   dehydration:	   two	   xylene	  
washes	   (5	  min	  each),	   followed	  by	  two	  100%	  ethanol	  rinses	   (5	  min	  each),	   followed	  by	  95%	  ethanol,	  
70%	  ethanol,	   50%	  ethanol,	   30%	  ethanol,	   followed	  by	  H2O	  and	   a	   Tris-­‐buffered	   saline	   solution	  with	  
Tween	   20	   (TBST)	   wash	   for	   5	   min	   on	   a	   shaker.	   After	   deparaffinization,	   slices	   were	   stained	   for	   15	  
minutes	   at	   room	   temperature	   (in	   the	  dark)	  with	   1%	  Thio-­‐S	   solution,	   differentiated	   in	   96%	  ethanol	  
and	  mounted	  with	  hydromount	  (National	  Diagnostics,	  Atlanta,	  USA)	  onto	  histological	  glass	  slides.	  	  
6b.	  	   Insulin	  staining	  
After	  deparaffinization,	  slices	  were	  immerged	  in	  3%	  H2O2-­‐methanol	  for	  10min	  at	  room	  temperature	  
to	   block	   endogenous	   peroxidase,	   rinsed	   in	   water	   and	   immerged	   in	   a	   solution	   containing	   5%	   of	  
normal	  goat	  serum,	  5%	  of	  normal	  horse	  serum	  and	  4%	  of	  BSA	  for	  1	  hour	  at	  room	  temperature	  as	  a	  
serum	  blocking	  in	  order	  to	  reduce	  background	  staining.	  Primary	  antibodies	  were	  added	  at	  a	  dilution	  
1:3	  (Polyclonal	  GP	  α	  Insulin,	  Dako,	  Baar,	  CH)	  for	  4	  hours	  at	  room	  temperature.	  After	  rinsing	  in	  water,	  
the	   slides	   were	   incubated	   with	   secondary	   antibodies	   (Donkey	   α	   GP,	   Jackson	   Biotechnology,	   St	  
Harbor,	  USA)	  at	  a	  dilution	  of	  1:500	  for	  1	  hour	  at	  room	  temperature.	  After	  another	  rinsing	  with	  water	  
the	  slices	  were	  incubated	  for	  30	  minutes	  at	  room	  temperature	  with	  Vectastain	  ABC	  reagent	  (PK-­‐600	  
Standard,	   Vector	   Laboratories,	   Burlingame,	   USA).	   The	   slides	   were	   rinsed	   again	   with	   water	   and	  
incubated	  for	  about	  7	  minutes	  with	  DAB	  reagent	  (3,3’-­‐diaminobenzidine	  tetrahydrochloride,	  Thermo	  
Scientific,	  Waltham,	  USA)	  at	  a	  dilution	  of	  1:10,	  at	  room	  temperature.	  The	  reaction	  was	  stopped	  with	  
water.	   The	   slides	   were	   then	   incubated	   for	   1-­‐3	   minutes	   in	   Couterstain	   Hem	   alum	   solution	   (Roth,	  
Zurich,	   CH).	   After	   dehydration,	   the	   slices	   were	   mounted	   with	   mounting	   medium	   (Eukitt,	   Sigma	  
Aldrich,	  St	  Louis,	  USA).	  
7.	  	   Statistics	  
All	   statistics	   were	   performed	   using	   the	   software	   Graphpad	   Prism	   5	   (San	   Diego,	   USA).	   	   One-­‐way	  
analysis	   of	   variances	   (ANOVA)	   and	   Tukey	   test	   for	   post	   hoc	   test	   were	   used.	   A	   p	   value	   <0.05	   was	  






Homozygous	  mice	  developed	  diabetes	  between	  10	  and	  12	  weeks	  of	  age.	  Fasting	  hyperglycaemia,	  
glucose	  intolerance	  and	  impaired	  insulin	  secretion	  were	  observed	  in	  both	  the	  homozygous-­‐PBS	  
(homo-­‐PBS)	  and	  homozygous-­‐antibody	  (homo-­‐AB)	  group	  (see	  Fig.	  2,	  4,	  5,	  6	  and	  7).	  Some	  mice	  died	  
spontaneously	  between	  10	  and	  12	  weeks	  of	  age	  in	  both	  homozygous	  groups,	  presumably	  following	  
complications	  due	  to	  their	  severe	  diabetic	  phenotype.	  The	  final	  number	  of	  animals	  was	  12	  mice	  in	  
the	  homo-­‐PBS	  and	  13	  mice	  in	  the	  homo-­‐AB	  group.	  Hemizygous	  mice	  (n=10)	  did	  not	  develop	  a	  
diabetic	  phenotype	  at	  any	  time	  during	  the	  course	  of	  the	  study.	  
2. Body	  weight	  
Baseline	  body	  weight	  was	  determined	  at	  4	  weeks	  of	  age,	  before	  mice	  were	  randomly	  assigned	  to	  
their	  respective	  groups	  and	  showed	  no	  significant	  difference	  among	  the	  groups.	  After	  4	  weeks	  from	  
the	  beginning	  of	  the	  immunization	  protocol,	  i.e.	  at	  an	  age	  of	  approximately	  8	  weeks,	  both	  homo-­‐PBS	  
and	  homo-­‐AB	  showed	  lower	  body	  weight	  in	  comparison	  to	  the	  hemi-­‐PBS	  control	  group.	  At	  this	  time	  
point,	  mean	  body	  weight	  of	  the	  homo-­‐PBS	  and	  the	  homo-­‐AB	  mice	  was	  about	  8%	  less	  than	  that	  of	  the	  
hemi-­‐PBS	  mice.	  However,	  no	  difference	  in	  body	  weight	  was	  observed	  between	  the	  homo-­‐PBS	  and	  
the	  homo-­‐AB	  group	  at	  any	  time	  point;	  suggesting	  no	  influence	  of	  the	  anti-­‐hIAPP	  antibody	  treatment	  
on	  body	  weight	  gain	  in	  this	  mouse	  strain.	  
	  
Fig	  11:	  Body	  weight	  in	  hemi-­‐PBS,	  homo-­‐PBS	  and	  homo-­‐AB	  mice	  from	  4	  to	  13	  weeks	  of	  age.	  
Treatment	  with	  either	  PBS	  or	  anti-­‐hIAPP	  antibodies	  was	  started	  at	  4	  weeks	  of	  age	  (§=p<0.05,	  
§§=p<0.01	  between	  the	  hemi-­‐PBS	  and	  the	  homo-­‐PBS	  group,	  *=p<0.05,	  **=p<0.01	  between	  the	  hemi-­‐
PBS	  and	  the	  homo-­‐AB	  group.	  Arrows	  indicate	  the	  time	  when	  ipGTTs	  were	  performed.	  Values	  are	  
shown	  as	  means	  ±	  SE.	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3. Fasting	  blood	  glucose	  levels	  
At	  one	  month	  of	  age,	  mean	  fasting	  blood	  glucose	  levels	  in	  the	  homo-­‐PBS	  group	  were	  slightly	  but	  
significantly	  higher	  than	  in	  the	  hemi-­‐PBS	  group	  (9.0	  ±	  0.8	  mmol/l	  and	  6.1	  ±	  0.4	  mmol/l,	  respectively,	  
p<0.05).	  At	  the	  same	  time	  point,	  fasting	  glucose	  concentration	  in	  the	  homo-­‐AB	  group	  (8.3	  ±	  0.9	  
mmol/l)	  was	  not	  significantly	  different	  from	  either	  the	  hemi-­‐PBS	  or	  the	  homo-­‐PBS	  group.	  	  
At	  two	  months	  of	  age,	  a	  tendency	  for	  higher	  fasting	  glucose	  levels	  was	  observed	  in	  the	  homo-­‐PBS	  
group	  (12.3	  ±	  2.5	  mmol/l)	  compared	  to	  the	  hemi-­‐PBS	  group	  (6.0	  ±	  0.4	  mmol/l),	  though	  the	  difference	  
was	  not	  statistically	  significant.	  Fasting	  glycaemia	  in	  the	  homo-­‐AB	  group	  was	  significantly	  higher	  (17.4	  
±	  3.3	  mmol/l)	  in	  comparison	  with	  the	  hemi-­‐PBS	  group	  but	  did	  not	  differ	  from	  the	  levels	  in	  the	  homo-­‐
PBS	  mice.	  
After	  three	  months	  of	  age,	  fasting	  glucose	  levels	  in	  the	  homo-­‐PBS	  and	  homo-­‐AB	  mice	  were	  about	  2-­‐
2.5	  times	  higher	  than	  values	  measured	  at	  one	  month	  of	  age.	  However,	  blood	  glucose	  levels	  in	  the	  
hemi-­‐PBS	  were	  significantly	  different	  only	  compared	  to	  the	  homo-­‐AB	  group	  but	  not	  to	  the	  homo-­‐PBS	  
group;	  this	  may	  have	  been	  due	  to	  the	  large	  variability	  within	  the	  homo-­‐PBS	  group.	  Fasting	  blood	  
glucose	  values	  in	  the	  homo-­‐PBS	  group	  and	  the	  homo-­‐AB	  group	  did	  not	  differ	  at	  any	  time	  point	  
(Fig.12).	  	  	  
	  
Fig	  12:	  Fasting	  blood	  glucose	  level	  (after	  12h	  fasting),	  in	  hemi-­‐PBS,	  homo-­‐PBS	  and	  homo-­‐AB	  group,	  at	  
one,	  two	  and	  three	  months	  of	  age.	  ANOVA	  showed	  a	  significant	  increase	  in	  the	  fasting	  blood	  glucose	  
level	  in	  homo-­‐PBS	  compared	  to	  hemi-­‐PBS	  mice	  at	  one	  month	  of	  age	  (§=p<0.05).	  A	  significant	  increase	  
of	  fasting	  blood	  glucose	  in	  the	  homo-­‐AB	  compared	  to	  the	  hemi-­‐PBS	  group	  was	  observed	  at	  two	  and	  







4. Fasting	  insulin	  levels	  
At	  one	  month	  of	  age,	  fasting	  insulin	  levels	  in	  the	  hemi-­‐PBS	  group	  (0.61	  ±	  0.1	  µg/l)	  were	  similar	  to	  the	  
levels	  measured	  in	  the	  homo-­‐PBS	  (0.51	  ±	  0.1	  µg/l)	  and	  homo-­‐AB	  (0.60	  ±	  0.04	  µg/l).	  
At	  two	  months	  of	  age,	  insulin	  concentrations	  in	  homo-­‐PBS	  (0.27	  ±	  0.10	  µg/l)	  and	  homo-­‐AB	  mice	  (0.36	  
±	  0.10	  µg/l)	  were	  similar	  and	  did	  not	  significantly	  differ	  from	  the	  hemi-­‐PBS	  group	  (0.39	  ±	  0.10	  µg/l).	  
However,	  in	  all	  three	  groups	  of	  mice,	  insulin	  levels	  tended	  to	  decrease	  in	  comparison	  with	  the	  values	  
measured	  at	  one	  month	  of	  age.	  
At	  three	  months	  of	  age,	  a	  tendency	  for	  lower	  fasting	  insulin	  levels	  in	  the	  homo-­‐PBS	  (0.30	  ±	  0.09	  µg/l)	  
and	  homo-­‐AB	  (0.21	  ±	  0.06	  µg/l)	  groups	  in	  comparison	  with	  the	  hemi-­‐PBS	  (0.50	  ±	  0.1	  µg/l)	  group	  was	  
observed,	  however,	  it	  did	  not	  reach	  statistically	  significance.	  The	  homo-­‐AB	  group	  showed	  a	  
significant	  decrease	  in	  fasting	  insulin	  concentration	  between	  the	  first	  and	  the	  third	  month	  of	  age	  
(P<0.01).	  	  
	  
Fig.13:	  Fasting	  insulin	  levels	  (after	  12h	  fasting)	  at	  one,	  two	  and	  three	  month	  of	  age	  in	  the	  hemi-­‐PBS,	  
homo-­‐PBS	  and	  homo-­‐AB	  group.	  No	  statistically	  significant	  differences	  were	  observed	  between	  the	  
groups	  at	  any	  time	  point.	  The	  homo-­‐AB	  group	  showed	  a	  significant	  decrease	  in	  fasting	  insulin	  levels	  
between	  one	  and	  three	  months	  of	  age	  (++	  =p<0.01).	  
5. Glycaemia	  during	  ipGTT	  
During	  the	  first	  ipGTT	  conducted	  at	  one	  month	  of	  age,	  i.e.	  before	  any	  treatment	  was	  started,	  
baseline	  glycaemia	  was	  significantly	  elevated	  in	  the	  homo-­‐PBS	  group	  in	  comparison	  with	  the	  hemi-­‐
PBS	  group	  (p<0.05).	  Plasma	  glucose	  levels	  were	  significantly	  higher	  at	  30	  (p<0.01)	  and	  60	  (p<0.01)	  
minutes	  in	  both	  homo-­‐PBS	  and	  homo-­‐AB	  groups	  compared	  with	  the	  hemi-­‐PBS	  group	  (see	  Fig.14).	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However,	  glucose	  areas	  under	  the	  curve	  (AUC)	  above	  the	  respective	  baseline	  were	  similar	  in	  all	  
groups	  (see	  Fig.17).	  
At	  two	  months	  of	  age,	  i.e.	  four	  weeks	  after	  the	  first	  treatment,	  baseline	  glycaemia	  tended	  to	  be	  
higher	  in	  the	  homo-­‐PBS	  group	  compared	  to	  the	  hemi-­‐PBS	  group	  and	  was	  significantly	  higher	  in	  the	  
homo-­‐AB	  group	  compared	  to	  the	  hemi-­‐PBS	  group	  (p<0.05,	  see	  Fig.	  15).	  Glucose	  concentrations	  in	  the	  
homozygous	  groups	  were	  significantly	  higher	  at	  30	  and	  60	  minutes	  compared	  to	  the	  values	  observed	  
in	  the	  hemi-­‐PBS	  group	  (p<0.01	  at	  both	  time	  points).	  In	  the	  homo-­‐AB	  group,	  glycaemia	  remained	  
significantly	  higher	  until	  120	  minutes	  after	  glucose	  injection	  (p<0.05).	  The	  AUC	  of	  both	  homo-­‐PBS	  and	  
homo-­‐AB	  groups	  were	  higher	  compared	  to	  AUC	  of	  the	  hemi-­‐PBS	  group,	  even	  though	  the	  difference	  
was	  not	  significant.	  AUCs	  were	  not	  significantly	  different	  between	  the	  homo-­‐PBS	  and	  the	  homo-­‐AB	  
group	  (see	  Fig.	  17).	  	  
At	  three	  months	  of	  age,	  baseline	  glycaemia	  was	  higher	  in	  the	  homo-­‐PBS	  and	  significantly	  increased	  in	  
the	  homo-­‐AB	  group	  (p<0.01)	  in	  comparison	  with	  the	  hemi-­‐PBS	  group.	  Glycaemia	  was	  significantly	  
higher	  from	  15	  to	  120	  minutes	  after	  glucose	  injection	  in	  both	  homo-­‐PBS	  and	  homo-­‐AB	  group	  
compared	  with	  hemi-­‐PBS	  group	  (see	  Fig.	  16).	  However,	  there	  were	  no	  differences	  in	  the	  AUCs	  above	  
baseline	  among	  the	  groups	  (see	  Fig.	  17).	  
	  
Fig.	  14:	  Glycaemia	  during	  ipGTT	  in	  one-­‐month	  old	  mice.	  ANOVA	  showed	  a	  significant	  increase	  in	  
glycaemia	  at	  30	  and	  60	  minutes	  after	  glucose	  injection	  in	  both	  homo-­‐AB	  and	  homo-­‐PBS	  (**=p<0.01,	  




Fig.	  15:	  Glycaemia	  during	  ipGTT	  in	  two-­‐month	  old	  mice.	  ANOVA	  showed	  a	  significant	  increase	  in	  
glycaemia	  at	  30	  and	  60	  and	  120	  minutes	  after	  glucose	  injection	  in	  both	  homo-­‐AB	  and	  homo-­‐PBS	  (*	  
p<0.05,	  **=p<0.01,	  §§	  p<0.01,	  respectively)	  compared	  with	  hemi-­‐PBS	  group.	  There	  is	  no	  significant	  
difference	  between	  the	  groups	  at	  baseline.	  Values	  are	  shown	  as	  means	  ±	  SE.	  
	  
Fig.	  16:	  Glycaemia	  during	  ipGTT	  in	  three-­‐month	  old	  mice.	  ANOVA	  showed	  a	  significant	  increase	  in	  
glycaemia	  at	  15,	  30,	  60,	  and	  120	  minutes	  after	  glucose	  injection	  in	  both	  homo-­‐AB	  and	  homo-­‐PBS	  (*	  
=p<0.05,	  **=	  p<0.01,	  ***	  =p<0.001,	  §=	  p<0.05,	  §§	  =p<0.01,	  respectively),	  in	  comparison	  with	  the	  
hemi-­‐PBS	  group.	  There	  is	  no	  significant	  difference	  between	  the	  groups	  at	  baseline	  Values	  are	  shown	  
as	  mean	  ±	  SE.	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Fig.	  17:	  Area	  under	  the	  curve	  of	  glycaemia	  (blood	  glucose	  in	  mmol/l/240	  minutes)	  above	  respective	  
baseline	  levels	  during	  ipGTTs	  in	  hemi-­‐PBS,	  homo-­‐PBS	  and	  homo-­‐AB,	  at	  one,	  two	  and	  three	  months	  of	  
age.	  Values	  are	  shown	  as	  mean	  ±	  SE.	  	  
6. Insulinemia	  during	  ipGTT	  
Unexpectedly,	  plasma	  insulin	  levels	  did	  not	  increase	  after	  glucose	  injection	  in	  any	  of	  the	  groups.	  At	  
one	  month	  of	  age,	  glucose-­‐stimulated	  insulin	  response	  in	  the	  hemi-­‐PBS	  group	  showed	  a	  small	  
increase	  15	  minutes	  after	  glucose	  injection	  and	  seemed	  to	  be	  higher	  at	  all	  time	  points	  as	  compared	  
to	  both	  homozygous	  groups.	  Nevertheless,	  the	  difference	  was	  significant	  only	  at	  60	  minutes.	  Insulin	  
levels	  were	  similar	  in	  both	  homo-­‐PBS	  and	  homo-­‐AB	  groups	  at	  all	  time	  points	  (Fig.18).	  	  
At	  two	  months	  of	  age,	  the	  hemi-­‐PBS	  group	  showed	  a	  similar	  pattern	  of	  insulin	  response	  to	  glucose	  as	  
shown	  at	  one	  month	  of	  age,	  though,	  mean	  insulin	  levels	  were	  lower.	  Plasma	  insulin	  concentration	  in	  
the	  hemi-­‐PBS	  group	  was	  higher	  from	  30	  to	  120	  minutes	  after	  glucose	  injection	  as	  compared	  to	  both	  
homozygous	  groups	  (Fig.19).	  
At	  three	  months	  of	  age,	  the	  insulin	  concentration	  during	  the	  ipGTT	  was	  similar	  among	  the	  three	  
groups	  except	  that	  at	  120	  minutes,	  when	  both	  homozygous	  groups	  had	  lower	  insulin	  levels	  
compared	  to	  the	  hemi-­‐PBS	  group	  (Fig.20).	  When	  data	  were	  examined	  as	  change	  over	  time,	  mean	  
insulin	  levels	  seemed	  to	  decrease	  over	  time	  in	  all	  groups.	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Fig.	  18:	  Insulinemia	  during	  ipGTT	  in	  one	  month	  old	  mice.	  ANOVA	  showed	  a	  significant	  decrease	  in	  
insulin	  levels	  in	  both	  homo-­‐PBS	  and	  homo-­‐AB	  group	  compared	  to	  the	  hemi-­‐PBS	  group	  at	  60	  minutes	  
after	  glucose	  injection	  (§=	  p<0.05,	  *	  =p<0.05,	  respectively).	  Values	  are	  shown	  as	  means	  ±	  SE.	  
	  
	  
Fig.	  19:	  Insulinemia	  during	  ipGTT	  in	  two-­‐month	  old	  mice.	  The	  values	  are	  shown	  as	  means	  ±	  SE.	  
ANOVA	  showed	  a	  significant	  decrease	  in	  insulin	  levels	  in	  homo-­‐PBS	  and	  homo-­‐AB	  group	  in	  
comparison	  with	  the	  hemi-­‐PBS	  group,	  at	  30,	  60	  and	  120	  minutes	  after	  glucose	  injection	  (§	  p<0.05,	  §§	  
=p<0.01,*=	  p<0.05,	  **	  =p<0.01,	  respectively).	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Fig.	  20:	  Insulinemia	  during	  ipGTT	  in	  three-­‐month	  old	  mice.	  The	  values	  are	  shown	  as	  means	  ±	  SE.	  
ANOVA	  showed	  a	  significant	  decrease	  in	  insulin	  level	  in	  both	  homo-­‐PBS	  and	  homo-­‐AB	  group	  in	  
comparison	  with	  the	  hemi-­‐PBS	  group	  at	  120	  minutes	  after	  glucose	  injection	  (§	  =p<0.05,	  *	  =p<0.05,	  
respectively).	  
The	  glucose-­‐induced	  changes	  in	  plasma	  insulin	  were	  unexpected	  in	  all	  three	  groups	  of	  mice,	  meaning	  
that	  insulin	  levels	  decreased	  rather	  than	  increased	  after	  glucose	  injection.	  For	  comparison	  purposes,	  
an	  ipGTT	  was	  performed	  in	  a	  group	  of	  untreated	  12	  weeks	  old	  C57Bl/6	  male	  mice	  (n=3),	  from	  which	  
published	  references	  values	  on	  insulin	  levels	  during	  ipGTTs	  are	  available	  (K.	  Kaku	  et	  al.,	  1998).	  In	  
these	  mice,	  insulin	  peaked	  15	  minutes	  after	  glucose	  injection	  and	  then	  decreased	  to	  levels	  lower	  
than	  baseline	  (see	  Fig.	  21);	  thus,	  mimicking	  the	  insulin	  response	  to	  glucose	  reported	  in	  the	  literature	  
(K.	  Kaku	  et	  al.,	  1998).	  Nonetheless,	  the	  insulin	  response	  was	  relatively	  small	  but	  the	  AUC	  of	  insulin	  
was	  positive,	  while	  the	  calculated	  AUCs	  above	  respective	  baselines	  of	  the	  hemi-­‐PBS,	  homo-­‐PBS	  and	  
homo-­‐AB	  at	  one,	  two	  and	  three	  months	  of	  ages	  were	  all	  negative	  (Fig.	  22).	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Fig.	  21:	  Insulinemia	  during	  ipGTT	  in	  three	  C57BL/6	  mice.	  Values	  are	  shown	  as	  mean	  ±	  SE.	  
	  
Fig	  22:	  Area	  under	  the	  curve	  of	  the	  plasma	  insulin	  (μg/l/120minutes)	  level	  during	  ipGTT	  in	  C57Bl/6	  
control	  mice	  (n=3)	  compared	  to	  the	  AUCs	  of	  the	  hemi-­‐PBS,	  homo-­‐PBS	  and	  homo-­‐AB	  group.	  Values	  
are	  shown	  as	  mean	  ±	  SE	  and	  are	  expressed	  relative	  to	  the	  respective	  baselines.	  
7. Thioflavin-­‐S	  staining	  of	  pancreas	  
At	  the	  end	  of	  the	  study,	  the	  mice	  were	  euthanized	  and	  the	  pancreas	  collected	  for	  histological	  
analysis.	  Thio-­‐S	  staining	  was	  performed	  to	  detect	  the	  presence	  of	  amyloid	  deposits	  in	  the	  pancreas	  of	  
the	  experimental	  mice.	  According	  to	  the	  literature	  (M.	  Couce	  et	  al,	  1996;	  J.	  Janson	  et	  al.,	  1996),	  Thio-­‐
S-­‐positive	  extracellular	  amyloid	  deposition	  should	  not	  be	  present	  in	  hemizygous	  mice	  while	  it	  should	  
be	  visible	  under	  electron	  microscopy	  in	  homozygous	  mice	  (R.L.	  Hull	  et	  al.,	  2005).	  Pancreas	  sections	  
from	  hemizygous	  animals	  were	  therefore	  used	  as	  a	  negative	  control.	  	  
As	  shown	  in	  Fig.	  23,	  extracellular	  amyloid	  deposits	  were	  not	  detected	  in	  the	  pancreas	  of	  both	  
homozygous	  groups.	  As	  positive	  control,	  pancreata	  from	  4.5	  months	  old	  heterozygous	  mice	  with	  a	  
different	  background,	  (FVB(h-­‐IAPP)xDBA/2J),	  fed	  with	  high	  fat	  diet,	  were	  used.	  In	  previous	  studies	  
(R.L.	  Hull	  et	  al.,	  2005),	  this	  model	  showed	  visible	  extracellular	  amyloid	  deposition	  under	  light	  
microscopy.	  The	  DBA/2J	  background	  is	  believed	  to	  be	  determinant	  for	  the	  magnitude	  of	  islet	  amyloid	  
formation,	  although	  the	  mechanism	  is	  not	  yet	  completely	  clear.	  It	  is	  believed	  that	  an	  increased	  
susceptibility	  to	  dietary	  fat-­‐related	  changes	  and	  an	  increased	  insulin	  release	  may	  play	  a	  role	  for	  the	  
extent	  of	  the	  extracellular	  deposition.	  Fig.	  24	  shows	  Thio-­‐S-­‐positive	  staining	  in	  the	  pancreas	  section	  




















Fig.23:	  Light	  microscope	  pictures	  of	  Thio-­‐S-­‐	  	  positive	  staining	  in	  pancreas	  sections	  from	  homo-­‐PBS,	  
homo-­‐AB	  and	  hemi-­‐PBS.	  A.	  Homo-­‐AB	  group;	  B.	  Homo-­‐PBS	  group;	  C.	  Hemi-­‐PBS	  group.	  Amyloid	  
deposition	  was	  not	  observed	  in	  any	  of	  the	  groups.	  	  
	  
	  
Fig.	  24:	  Light	  microscope	  pictures	  of	  Thio-­‐S-­‐positive	  staining	  in	  pancreas	  sections	  from	  one	  
heterozygous	  tg/-­‐	  FVB(h-­‐IAPP)xDBA/2J	  mouse	  at	  4.5	  months	  of	  age.	  Amyloid	  deposition	  was	  clearly	  
visible	  in	  large	  parts	  of	  the	  islets	  (arrow).	  	  
	  
8. Insulin	  staining	  of	  pancreas	  
Insulin	  staining	  showed	  a	  reduction	  in	  the	  average	  size	  of	  islets	  in	  both	  homozygous	  groups.	  Only	  a	  
few	  insulin-­‐positive	  cells	  could	  be	  observed	  in	  the	  islets	  of	  those	  groups,	  (Fig.	  26	  and	  27).	  In	  
comparison,	  islets	  in	  the	  pancreas	  of	  the	  hemizygous	  group	  (Fig.	  25)	  seemed	  to	  be	  bigger	  in	  size	  and	  
to	  contain	  more	  insulin-­‐positive	  stained	  β-­‐cells	  compared	  to	  both	  homozygous	  groups.	  However,	  no	  






	   	   	   	   	   	   	   	  
Fig.	  25:	  Insulin	  staining	  (brown)	  in	  pancreas	  sections	  of	  hemizygous-­‐PBS	  mice.	  The	  size	  and	  the	  








Fig.	  26:	  Insulin	  staining	  (brown)	  in	  pancreas	  sections	  of	  homo-­‐AB	  mice.	  Due	  to	  the	  loss	  of	  insulin	  
stained	  β-­‐cells,	  the	  size	  of	  islets	  (arrow)	  appeared	  to	  be	  smaller	  in	  comparison	  with	  insulin	  stained	  









Fig	  27:	  Insulin	  staining	  (brown)	  in	  pancreas	  sections	  of	  homo-­‐PBS	  mice.	  As	  for	  the	  homo-­‐AB	  group,	  





The	   aim	   of	   the	   present	   study	   was	   to	   test	   the	   therapeutic	   efficacy	   of	   a	   novel	   therapy	   for	   type-­‐2	  
diabetes	  mellitus	  based	  on	  high	  affinity	  human	  derived	  antibodies	  targeting	  pathologically	  misfolded	  
forms	  of	  human	  islet	  amyloid	  polypeptide	  (hIAPP)	  in	  a	  transgenic	  mouse	  model	  of	  T2DM	  expressing	  
hIAPP.	  	  
IAPP	   is	   a	   peptide	   hormone	   co-­‐secreted	   with	   insulin	   by	   pancreatic	   β-­‐cells.	   In	   T2DM,	   genetic	  
determinants	  and	  environmental	  factors	  lead	  to	  the	  development	  of	  insulin	  resistance	  followed	  by	  a	  
compensatory	   increase	   in	   β-­‐cell	   mass	   and	   insulin	   and	   IAPP	   secretion	   to	   maintain	   normal	   blood	  
glucose	  levels.	  The	  resulting	  high	  concentration	  of	  IAPP	  favours	  the	  formation	  of	  toxic	  IAPP	  oligomers	  
and	  eventually	  the	  deposition	  of	  IAPP	  fibrils	  which	  is	  found	  in	  more	  than	  90%	  of	  T2DM	  patients.	  The	  
deposition	   of	   IAPP	   correlates	   with	   the	   reduction	   in	   insulin	   producing	   β-­‐cells	   (A.	   Clark	   and	   M.R.	  
Nilsson,	  2004).	  	  
Our	  immunotherapeutic	  approach	  was	  based	  on	  the	  identification,	  characterization	  and	  recombinant	  
production	  of	  human-­‐derived	  monoclonal	  antibodies	  specific	   for	  toxic	  hIAPP	  aggregates	  from	  pools	  
of	   healthy	   donors	   or	   donors	   with	   mild	   forms	   or	   unusually	   slow	   progressing	   courses	   of	   T2DM.	  
Whereas	  most	  antibody-­‐based	  therapeutic	  approaches	  focus	  on	  humanized	  molecules,	  the	  method	  
described	  in	  this	  thesis	  had	  the	  principal	  advantage	  of	  a	  superior	  safety	  profile	  when	  compared	  with	  
engineered	   antibodies	   or	   antibodies	   isolated	   from	   non	   human-­‐sources.	   Lead	   antibody	   candidates	  
were	  validated	   in	  vitro	   for	   their	  affinity	  and	  selectivity	   to	  pathological	  hIAPP	   in	  pancreatic	   tissue	  of	  
human	  diabetic	  subjects.	  The	  NI	  203.26C11	  antibody	  showed	  high	  affinity	  for	  pathological	  hIAPP	  and	  
no	  binding	  to	  the	  native	  conformation	  of	  physiological	  monomeric	  hIAPP	  in	  healthy	  subjects.	  Thus,	  NI	  
203.26C11	  was	  selected	  for	  validation	  in	  vivo	  in	  transgenic	  mice	  expressing	  hIAPP.	  	  
IAPP	   in	  mice	  and	  rats	  shares	  a	   large	  degree	  of	  homology	  with	  human	   IAPP	  but	  differs	   from	  human	  
IAPP	  by	  substitution	  of	  proline	  residues	  in	  the	  amyloidogenic	  portion	  of	  IAPP.	  Therefore,	  mouse	  and	  
rat	   IAPP	   does	   not	   form	   amyloid	   tendrils	   or	   oligomers	   nor	   do	  mice	   or	   rats	   spontaneously	   develop	  
diabetes	   in	  midlife.	   Thus,	   in	   order	   to	   study	   the	   diabetogenic	   role	   of	   hIAPP	   in	  mice,	   rodent	  model	  
transgenic	  for	  hIAPP	  were	  developed.	  	  
In	  the	  present	  study,	  the	  therapeutic	  efficacy	  of	  the	  NI	  203.26C11	  antibody	  in	  clearing	  existing	  hIAPP	  
deposits	   and	   in	   preventing	   further	   build-­‐up	   was	   studied	   in	   FVB/N-­‐Tg(Ins2-­‐IAPP)RHFSoel/J	   mice	  
(RIPHAT	   mice).	   The	   RIPHAT	   mice	   express	   hIAPP	   under	   the	   regulatory	   control	   of	   the	   rat	   insulin	   II	  
promoter.	  While	  hemizygous	  mice	  show	  no	  symptoms	  of	   spontaneous	  disease,	  homozygous	  males	  
spontaneously	   develop	   diabetes	   mellitus	   due	   to	   β-­‐cell	   death,	   associated	   with	   impaired	   insulin	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secretion	  (hypoinsulinemia),	  hyperglycemia,	  and	  abnormal	  intracellular	  aggregates	  of	  hIAPP.	  For	  this	  
study,	  male	   homozygous	  mice	  were	   used	  because	   females	   showed	   a	  more	   subtle	   phenotype	  with	  
slower	  progression	  or	  absence	  of	  diabetes	   (J.	   Janson	  et	  al.,	  1996).	  Mice	  were	  fed	  ad	   libitum	  with	  a	  
conventional	   chow	   diet,	   in	   order	   to	   minimize	   any	   confounding	   effect	   due	   to	   peripheral	   insulin	  
resistance	  induced	  by	  dietary	  fat	  overload.	  	  
Consistent	   with	   the	   literature	   (M.	   Couce	   et	   al,,	   1996),	   hemizygous	   control	   mice	   treated	   with	   PBS	  
(hemi-­‐PBS)	  did	  not	  develop	  diabetes	  mellitus	  and	  showed	  no	  changes	  in	  fasting	  blood	  glucose	  level	  
and	  glucose	  tolerance	  over	  the	  whole	  experimental	  time.	  	  
Further,	  homozygous	  mice	  treated	  with	  PBS	   (homo-­‐PBS)	  showed	  significantly	  higher	  glycaemia	  and	  
impaired	  glucose	  tolerance	  compared	  to	  the	  hemi-­‐PBS	  group	  from	  one	  month	  of	  age.	  The	  treatment	  
with	  the	  NI	  203-­‐26C11	  antibody	  did	  not	  improve	  fasting	  glycaemia	  or	  glucose	  tolerance	  in	  homo-­‐AB	  
mice	   compared	   to	   the	   homo-­‐PBS.	   In	   fact,	   both	   groups	   of	   homozygous	   mice,	   independently	   from	  
treatment	  allocation,	  developed	  a	  diabetic	  phenotype	  in	  comparison	  to	  the	  hemi-­‐PBS	  mice.	  
A	  potential	  explanation	  for	  the	  lack	  of	  effect	  of	  the	  NI	  203.26C11	  antibody	  on	  basal	  glycemia	  might	  
be	  that	  the	  twelve	  hours	  fasting	  period	  lowered	  blood	  glucose	  level	  to	  a	  level	  that	  prevented	  us	  from	  
observing	  any	  difference	  between	  the	  homozygous	  groups.	  Nevertheless,	  both	  homozygous	  groups	  
showed	   severe	   glucose	   intolerance	   already	   at	   the	   first	   ipGTT,	   which	   worsened	   with	   time,	   in	  
comparison	  with	  the	  hemi-­‐PBS	  group.	  In	  fact,	  blood	  glucose	  levels	  during	  the	  first	  15-­‐30	  min	  of	  the	  
second	   and	   third	   ipGTT	   were	   even	   higher	   than	   the	   upper	   detection	   limit	   of	   the	   glucometer	   (33	  
mmol/l).	   In	   such	   cases,	   an	   estimate	   of	   blood	   glycemia	  was	   obtained	   by	   diluting	   blood	  with	   saline	  
(1:1).	  However,	  this	  dilution	  procedure	  revealed	  to	  be	  imprecise	  because	  no	  consistent	  values	  were	  
obtained	   after	   linear	   dilution.	   Nonetheless,	   to	   the	   best	   of	   our	   knowledge,	   there	   are	   currently	   no	  
comparable	  commercially	  available	  devices	   that	  could	  measure	  glycemia	  above	  33	  mmol/l	   in	  mice.	  
To	   overcome	   this	   problem,	   glucose	   levels	   could	   have	   been	   measured	   in	   plasma	   by	   the	  
hexokinase/glucose-­‐6-­‐phosphate	   dehydrogenase	   reaction.	   In	   this	   case,	   however,	   larger	   volumes	  of	  
blood	  would	  have	  been	  required	  at	  each	  time	  point	  thus	  allowing	  less	  frequent	  samplings.	  	  
Insulin	   levels	  were	  significantly	   lower	   in	  the	  two	  homozygous	  groups	   in	  comparison	  with	  the	  hemi-­‐
PBS	   group.	   This	   finding	  was	   expected	   considering	   the	   glucose	   intolerance	   and	   the	   low	   number	   of	  
insulin-­‐positive	   cells	   which	   were	   observed	   in	   the	   homozygous	   mice.	   However,	   insulin	   levels	   were	  
unexpectedly	   low	   also	   in	   the	   hemi-­‐PBS	   group.	   In	   this	   group,	   glucose-­‐induced	   increases	   of	   insulin	  
reached	  a	  peak	  15	  min	  after	  glucose	  injection,	  but	  the	  peak	  was	  only	  observed	  during	  the	  first	  and	  
second	  ipGTT.	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Plasma	  levels	  of	  insulin	  have	  never	  been	  measured	  during	  ipGTT	  in	  this	  mouse	  strain.	  In	  the	  
literature,	  glucose	  tolerance	  of	  the	  RIPHAT	  mice	  has	  always	  been	  tested	  with	  oral	  glucose	  tolerance	  
tests.	  The	  oral	  administration	  of	  glucose	  in	  glucose	  tolerance	  tests	  triggers	  higher	  insulin	  secretion	  
compared	  to	  ipGTTs,	  because	  oral	  glucose	  activates	  the	  secretion	  of	  endogenous	  incretins	  like	  GLP-­‐1	  
and	  GIP	  (S.	  Andrikopoulos	  et	  al.,	  2008).	  Because	  in	  this	  study,	  glucose	  was	  administered	  
intraperitoneally	  during	  the	  tolerance	  tests,	  glucose-­‐induced	  insulin	  secretion	  was	  not	  augmented	  by	  
incretin	  effects.	  We	  presumed	  that	  as	  a	  result,	  insulin	  levels	  were	  in	  many	  cases	  lower	  than	  the	  
detection	  limit	  (0.025μg/l)	  of	  the	  ELISA	  assay	  and	  therefore	  could	  not	  be	  measured	  accurately.	  	  
In	   the	   literature,	   insulin	   levels	   in	  C57BL/6J	  mice	  during	   ipGTT	  are	  within	   the	  measurable	   ranges	  of	  
typical	   ELISAs	   (K.	   Kaku	   et	   al.,	   1988).	   Therefore,	   in	   order	   to	   exclude	   any	   error	   of	   the	   technical	  
execution	  of	   the	  ELISA,	  we	  performed	  an	   ipGTT	   in	  C57BL/6J	  mice	  and	  measured	  plasma	   insulin.	  As	  
expected,	   plasma	   insulin	   in	   C57BL/6J	  mice	  was	   in	   the	   same	   range	   as	   reported	   in	   the	   literature	   (K.	  
Kaku	  et	  al.,	  1988)	  suggesting	  that	  the	  very	  low	  insulin	  levels	  observed	  in	  the	  RIPHAT	  mice	  may	  be	  the	  
result	  of	  considerably	  lower	  levels	  of	  systemic	  insulin	  in	  this	  strain.	  	  
Other	   conditions	   that	   may	   also	   have	   contributed	   to	   interfere	   with	   the	   measurement	   of	   plasma	  
insulin	   is	   the	   presence	   of	   hemolysis	   in	   plasma	   samples,	   especially	   at	   the	   latest	   time	   point	   of	   the	  
ipGTT.	  Hemolysis	  can	  interfere	  with	  the	  detection	  of	  insulin	  by	  the	  ELISA	  assay,	  as	  it	  is	  mentioned	  in	  
manufacturer’s	  instructions.	  Because	  the	  quantity	  of	  blood	  in	  multiple	  samples	  withdrawn	  is	  limited	  
in	  mice,	   insulin	   levels	  were	  not	  measured	   in	  duplicates.	  Moreover,	   ipGTTs	  were	  performed	  after	  a	  
twelve	  hours	  overnight	  fasting,	  which	  may	  have	  contributed	  to	  low	  insulin	  levels	  (S.	  Andrikopoulos	  et	  
al.,	  2008).	  	  
In	   the	   literature	   (M.	   Couce	   et	   al.,	   1996),	   diabetes	   onset	   in	   the	   RIPHAT	   homozygous	  male	  mice	   is	  
described	  between	  4-­‐8	  weeks	  of	  age	  with	  spontaneous	  death	  around	  16	  weeks	  of	  age.	  The	  absence	  
of	  consensual	  reference	  values	  of	  fasting	  glycemia	  and	  in	  glucose	  tolerance	  for	  a	  precise	  diagnosis	  of	  
T2DM	  in	  mice	  prevented	  us	  from	  defining	  the	  exact	  time	  point	  of	  diabetes	  onset	  in	  the	  homozygous	  
mice	  of	  our	  study.	  Furthermore,	  the	  total	  amount	  of	  water	  consumption	  and	  urine	  production	  was	  
not	   measured.	   However,	   both	   homozygous	   groups	   presented	   with	   a	   polyuric	   and	   polydypsic	  
phenotype	  already	  around	  two	  months	  of	  age	  (personal	  observations).	  In	  other	  studies	  conducted	  in	  
mouse	  models	  for	  type	  1	  diabetes,	  animals	  with	  blood	  glucose	  concentrations	  equal	  to	  or	  over	  300	  
mg/dl	   (which	  corresponds	  approximately	   to	  16.7	  mmol/l)	  were	  considered	  diabetic	   (M.	  Graham	  et	  
al.,	  2011).	  According	  to	  these	  reference	  values,	  homo-­‐AB	  and	  homo-­‐PBS	  could	  have	  been	  considered	  
diabetic	  at	  two	  and	  three	  months	  of	  age,	  respectively.	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Thio-­‐S	  positive	  extracellular	  amyloid	  load	  was	  not	  detected	  under	  light	  microscopy	  in	  neither	  of	  the	  
experimental	  groups	  of	  mice.	  The	  lack	  of	  detectable	  Thio-­‐S	  positive	  amyloid	  deposition	  in	  our	  study	  
does	  not	  exclude	  the	  presence	  of	  small	  intracellular	  toxic	  oligomers.	  In	  fact,	  small	  intracellular	  hIAPP	  
aggregations	  have	  been	  described	   in	  pancreas	  section	   from	  RIPHAT	  homozygous	  mice	   (J.	   Janson	  et	  
al.,	  2006),	  however	  these	  observations	  were	  detected	  only	  through	  electron	  microscopy	  which	  was	  
not	  available	  for	  our	  study.	  	  
We	  observed	  a	  decrease	  of	  the	  insulin-­‐positive	  areas	  in	  sections	  of	  pancreata	  from	  both	  homozygous	  
groups	  in	  comparison	  to	  the	  hemi-­‐PBS	  group.	  This	  was	  accompanied	  by	  a	  reduction	  in	  the	  size	  of	  the	  
islets	   in	   both	   homo-­‐AB	   and	   homo-­‐PBS	   groups.	   These	   observations	   indicate	   that	   the	   loss	   of	   β-­‐cells	  
might	   not	   be	   directly	   related	   to	   the	   presence	   of	   extracellular	   IAPP	   fibrils,	   but	  might	   be	   caused	   by	  
other	  mechanisms.	  In	  fact,	  according	  to	  the	  literature,	  IAPP	  toxicity	  in	  the	  RIPHAT	  mice	  depends	  on	  
the	   high	   IAPP	   intracellular	   concentration	   in	   the	   pancreas	   which	   in	   turn	   induces	   accumulation	   of	  
polyubiquinated	  proteins	  ultimately	  leading	  to	  ER-­‐stress.	  Moreover,	  the	  presence	  of	  non	  fibrillar	  IAPP	  
formation	  may	   cause	  membrane	  damages,	   disruption	  of	   proteasome	  and	  be	   responsible	   for	   β-­‐cell	  
apoptosis,	  thus	  implying	  a	  direct	  cytotoxicity	  effect	  of	  soluble	  IAPP	  forms	  on	  β-­‐cells	  (C.J.	  Huang	  et	  al.,	  
2007).	  This	  may	  happen	  before	  extracellular	  amyloid	  can	  be	  detected	  with	  Thio-­‐S	  staining.	  	  
The	  phenotype	  of	  the	  RIPHAT	  homozygous	  male	  was	  very	  severe	  and	  progressed	  rapidly	  in	  our	  study.	  
Spontaneous	  death	  was	  observed	  during	  the	  experimental	  time	  in	  both	  homozygous	  groups.	  The	  NI	  
203.26C11	   antibody	   administration	   did	   not	   show	   beneficial	   effects	   in	   preventing	   or	   slowing	   the	  
progression	   of	   diabetes	   in	   this	   mouse	   strain.	   Nevertheless,	   the	   antibody	   administration	   was	   well	  
tolerated	  and	  did	  not	  elicit	  any	  toxic	  or	  systemic	  immunoreaction.	  The	  normal	  progression	  of	  T2DM	  
in	  humans	  is	  a	  chronic	  process	  that	  takes	  place	  over	  years	  (D.R.	  Whiting,	  2011).	  Hence,	  it	  is	  difficult	  
to	  predict	  the	  effect	  that	  a	  chronic	  anti-­‐amyloid	  antibody	  administration	  would	  have	  in	  humans.	  The	  
model	   used	   in	   our	   study	   presumably	   progressed	   too	   rapidly	   into	   a	   pathological	   phenotype	   which	  
does	  not	  reflect	  the	  physiopathology	  of	  the	  disease	  in	  humans.	  Therefore,	  other	  animal	  model	  may	  
be	  more	  appropriate	   to	  assess	   the	  efficiency	  of	   the	  antibodies	  and	   their	  potential	   contribution	   for	  
the	  treatment	  of	  T2DM	  in	  humans.	  
In	   this	   regard,	   a	   study	   currently	   assesses	   the	   effect	   of	   the	   NI	   203.26C11	   antibody	   in	   hIAPP	  
(hemizygous)/C57BL/6	   x	   DBA	   mice.	   These	   mice	   do	   not	   develop	   spontaneous	   T2DM,	   but	   have	  
impaired	  glucose	  tolerance	  during	  ipGTT	  due	  to	  decreased	  insulin	  secretion.	  They	  show	  extracellular	  
amyloid	  deposition	  and	  evidence	  for	  decrease	  β-­‐	  cell	  mass	  at	  about	  seven	  months	  of	  age	  (R.L.	  Hull	  et	  
al.,	  2003;	  R.L.	  Hull	  et	  al.,	  2005;	  F.	  Wang	  et	  al.,	  2001).	  The	  slower	  progression	  of	  the	  disease	  in	  these	  
mice	  makes	   them	  a	  more	  suitable	  model	   for	   the	  assessment	  of	   the	  therapeutic	  efficacy	  of	  human-­‐
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derived	   anti-­‐hIAPP	   antibodies.	   Furthermore,	   the	   effect	   of	   the	   NI	   203.26C11	   antibody	   is	   currently	  
under	  investigation	  in	  the	  so	  called	  RIPHAT	  rat	  model.	  RIPHAT	  rats	  present	  with	  a	  similar	  phenotype	  
as	  the	  RIPHAT	  mice	  but	  with	  a	  much	  slower	  progression	  of	  T2DM	  (A.E.	  Butler	  et	  al.,	  2004).	  	  
Similar	   approaches	  of	   immunotherapy	  were	  developed	   for	   several	   brain	  diseases	   involving	  protein	  
aggregation	  such	  as	  Alzheimer’s	  disease,	  Parkinson’s	  disease,	  and	  amyotrophic	  lateral	  sclerosis.	  The	  
dosage	  (10mg/kg)	  of	  the	  NI	  203.26C11	  antibody	  administered	  in	  this	  study	  was	  based	  on	  Alzheimer’s	  
trials	  in	  which	  antibodies	  were	  required	  to	  cross	  the	  blood/brain	  barrier	  and	  reach	  the	  targeted	  brain	  
areas.	  Targeting	  pancreatic	  islets	  via	  the	  systemic	  circulation	  may	  however	  more	  easily	  be	  achieved	  
and	  may	   then	   require	   lower	   concentrations	   of	   antibody.	   Thus,	   it	  might	   then	   be	   that	   the	   antibody	  
dosage	  used	  in	  the	  present	  study	  was	  too	  high	  and	  may	  have	  had	  neutralizing	  effect.	  Dose	  response	  
studies	  will	  be	  needed	  to	  test	  this	  hypothesis.	  
	  
In	  conclusion,	  administration	  of	  the	  human-­‐derived	  IAPP-­‐antibody	  NI	  203.26C11	  in	  RIPHAT	  mice	  was	  
safe	   and	   well	   tolerated.	   However,	   the	   immunotherapy	   did	   not	   improve	   glucose	   control,	   glucose	  
tolerance	   and	   insulin	   secretion	   nor	   was	   it	   effective	   in	   slowing	   the	   progression	   of	   diabetes	   in	   this	  
mouse	  model	  transgenic	  for	  hIAPP.	  Under	  the	  experimental	  conditions	  of	  this	  study,	  we	  believe	  that	  
the	   very	   rapid	   progression	   of	   islet	   degeneration	   in	   the	   transgenic	   mice	   may	   have	   prevented	   the	  
beneficial	  effects	  of	   the	   immunotherapy.	  Nevertheless,	  preliminary	  results	   in	  other	  rodents	  models	  
of	  T2DM	  showed	  that	  passive	   immunization	  with	  the	  IAPP-­‐antibody	  NI	  203.26C11	  could	  ameliorate	  
glucose	  control	  and	  insulin	  metabolism	  by	  targeting	  toxic	  aggregates	  of	  IAPP	  and	  reducing	  the	  loss	  of	  
pancreatic	  β-­‐cells.	  	  
Therefore,	  it	  may	  be	  concluded	  that	  the	  NI	  203.26C11	  antibody	  may	  represent	  a	  novel	  treatment	  for	  
T2DM.	  However,	   further	   in	   vivo	   studies	   are	   required	   to	   test	   the	   therapeutic	   efficacy	   of	   this	   novel	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